http://jnci.oxfordjournals.org/content/93/16/1204.full
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>Epoetin Treatment of Anemia Associated With Cancer Therapy: a Systematic Review and Meta-analysis of Controlled Clinical Trials
         
      </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/93/16/1204" />
      <meta content="/jnci/93/16/1204.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="Epoetin Treatment of Anemia Associated With Cancer Therapy: a Systematic Review and Meta-analysis of Controlled Clinical Trials"
            name="DC.Title" />
      <meta content="10.1093/jnci/93.16.1204" name="DC.Identifier" />
      <meta content="2001-08-15" name="DC.Date" />
      <meta content="Oxford University Press" name="DC.Publisher" />
      <meta content="Jerome Seidenfeld" name="DC.Contributor" />
      <meta content="Margaret Piper" name="DC.Contributor" />
      <meta content="Carole Flamm" name="DC.Contributor" />
      <meta content="Victor Hasselblad" name="DC.Contributor" />
      <meta content="James O. Armitage" name="DC.Contributor" />
      <meta content="Charles L. Bennett" name="DC.Contributor" />
      <meta content="Michael S. Gordon" name="DC.Contributor" />
      <meta content="Allan E. Lichtin" name="DC.Contributor" />
      <meta content="James L. Wade III" name="DC.Contributor" />
      <meta content="Steven Woolf" name="DC.Contributor" />
      <meta content="Naomi Aronson" name="DC.Contributor" />
      <meta content="Journal of the National Cancer Institute"
            name="citation_journal_title" />
      <meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
      <meta content="0027-8874" name="citation_issn" />
      <meta content="1460-2105" name="citation_issn" />
      <meta name="citation_author" content="Jerome Seidenfeld" />
      <meta name="citation_author" content="Margaret Piper" />
      <meta name="citation_author" content="Carole Flamm" />
      <meta name="citation_author" content="Victor Hasselblad" />
      <meta name="citation_author" content="James O. Armitage" />
      <meta name="citation_author" content="Charles L. Bennett" />
      <meta name="citation_author" content="Michael S. Gordon" />
      <meta name="citation_author" content="Allan E. Lichtin" />
      <meta name="citation_author" content="James L. Wade" />
      <meta name="citation_author" content="Steven Woolf" />
      <meta name="citation_author" content="Naomi Aronson" />
      <meta content="Epoetin Treatment of Anemia Associated With Cancer Therapy: a Systematic Review and Meta-analysis of Controlled Clinical Trials"
            name="citation_title" />
      <meta content="08/15/2001" name="citation_date" />
      <meta content="93" name="citation_volume" />
      <meta content="16" name="citation_issue" />
      <meta content="1204" name="citation_firstpage" />
      <meta content="1214" name="citation_lastpage" />
      <meta content="93/16/1204" name="citation_id" />
      <meta content="93/16/1204" name="citation_id_from_sass_path" />
      <meta content="jnci;93/16/1204" name="citation_mjid" />
      <meta content="10.1093/jnci/93.16.1204" name="citation_doi" />
      <meta content="http://jnci.oxfordjournals.org/content/93/16/1204.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/93/16/1204.full"
            name="citation_fulltext_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/93/16/1204.full.pdf"
            name="citation_pdf_url" />
      <meta content="http://jnci.oxfordjournals.org/content/93/16/1204"
            name="citation_public_url" />
      <meta content="11504766" name="citation_pmid" />
      <meta name="citation_section" content="Review" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/93/16/1203.short" rel="prev" />
      <link href="/content/93/16/1215.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-local-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-ac.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d29012663e1">var callbackToken='53731C7C98B276F';</script><script type="text/javascript" id="session-d29012663e3">
                      var subCode='oupjournal_sub';
                    </script><script type="text/javascript">
            var gAuthTimeStamp = '2015-10-27T12:14:22.536-07:00';
            var gSessionId = 'KUK9uAePr3rWOwZkns@fiw';
            var gAuthzRequired = 'false';
            var gAuthnMethods1 = 'ip';
            var gAuthnMethods2 = 'ip';
            var gAuthnIPs = '18.189.59.169';
            var gAuthnIndividuals = '';
            var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
            </script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
              src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
          MathJax.Hub.Queue(function() {
            gColTempResize = true;
            fixColHeights(1);
            gColTempResize = false;
          });
       </script><script type="text/javascript"
              src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
	    
	    
	    
	    var siqDOI = encodeURIComponent("10.1093/jnci/93.16.1204");
	    var siqIsOpenAccess = encodeURIComponent("");
	    var siqPubDate = encodeURIComponent("20010815");

	    if (siqDOI.length == 0) {
	        siqDOI = "UNKNOWN";
	    }
	    
	    
		
		
	    if (gAuthnIndividuals.length != 0) {
		if (gAuthnInstitutions.length != 0) {
		    authnEntity = encodeURIComponent(gAuthnIndividuals
		        + ',' + gAuthnInstitutions);
		} else {
		    authnEntity = encodeURIComponent(gAuthnIndividuals);
		}
	    } else {
	        authnEntity = encodeURIComponent(gAuthnInstitutions);
	    }

	    var commonString =
		'authSessionId=' + gSessionId + String.fromCharCode(0x26)
		+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
		+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
		+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
		+ 'authnInstitutions=' + authnEntity;

		
		
		
		

	    var gPageId = "pageid-content";
	    var gVariant = "full-text";

	    
		// Not completely done
		var eventType = "full-text";
		var accessType;
		if (siqIsOpenAccess == 'true') {
		    accessType = 'SOA';
		} else {
		    accessType = 'subscription';
		}
		    
		var NTPT_PGEXTRA =
		    commonString + String.fromCharCode(0x26)
		    + 'event_type=' + eventType + String.fromCharCode(0x26)
		    + 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
		    + 'access_type=' + accessType + String.fromCharCode(0x26)
		    + 'doi=' + siqDOI ;
		    
		

	    // alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
	</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-header.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-footer.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-sidebars.css" />
      <link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
      <link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
            href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
      <link rel="stylesheet" type="text/css" media="screen"
            href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
   <body class="general_page journal jnci">
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
           itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <noscript>
            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
                     JNCI J Natl Cancer Inst
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jnci/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution:  MIT Libraries</li>
                     <li class="no-left-border">
                        <a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F93%2F16%2F1204.full">
                           Sign In as Personal Subscriber
                           </a>
                        
                     </li>
                  </ul>           
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
                     class="breadcrumb_subject">Medicine &amp; Health</a></span></li>
            <li><a href="/">JNCI J Natl Cancer Inst</a></li>
            <li><a href="/content/93/16.toc">
                  <span xmlns="" class="volume-value">Volume 93</span>
                  <span xmlns="" class="issue-value"> Issue 16</span></a></li>
            <li>Pp. <span class="slug-pages">
                  1204-1214.
                  </span></li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top"
                    src="/resource/htmlfiles/advert.html?p=Top&amp;u=jnci.oxfordjournals.org/content/93/16/1204.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div id="content-block">
            <div class="article fulltext-view" itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Epoetin Treatment of Anemia Associated With Cancer Therapy: a Systematic Review and Meta-analysis of Controlled Clinical Trials</h1>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#sec-1" title="Methods" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  
                  <p id="p-1">Epoetin treatment offers an attractive but costly alternative to red blood cell transfusion for managing anemia associated
                     with cancer therapy. The goal of this review is to facilitate more efficient use of epoetin by 1) quantifying the effects
                     of epoetin on the likelihood of transfusion and on quality of life in patients with cancer treatment-related anemia and 2)
                     evaluating whether outcomes are superior when epoetin treatment is initiated at higher hemoglobin thresholds. Two independent
                     reviewers followed a prospective protocol for identifying studies. Outcomes data were combined with the use of a random-effects
                     meta-analysis model. Double-blind, randomized, controlled trials that minimized patient exclusions were defined as higher
                     quality for sensitivity analysis; randomized but unblinded trials and trials with excessive exclusions were included in the
                     meta-analysis but were defined as lower quality. Twenty-two trials (n = 1927) met inclusion criteria, and 12 (n = 1390) could
                     be combined for estimation of odds of transfusion. Epoetin decreased the percentage of patients transfused by 9%–45% in adults
                     with mean baseline hemoglobin concentrations of 10 g/dL or less (seven trials; n = 1080), by 7%–47% in those with hemoglobin
                     concentrations greater than 10 g/dL but less than 12 g/dL (seven trials; n = 431), and by 7%–39% in those with hemoglobin
                     concentrations of 12 g/dL or higher (five trials; n = 308). In sensitivity analysis, the combined odds ratio for transfusion
                     in epoetin-treated patients as compared with controls was 0.45 (95% confidence interval [CI] = 0.33 to 0.62) in higher quality
                     studies and 0.14 (95% CI = 0.06 to 0.31) in lower quality studies. The number of patients needed to treat to prevent one transfusion
                     is 4.4 for all studies, 5.2 for higher quality studies, and 2.6 for lower quality studies. Only studies with mean baseline
                     hemoglobin concentrations of 10 g/dL or less reported statistically significant effects of epoetin treatment on quality of
                     life; quality-of-life data were insufficient for meta-analysis. No studies addressed epoetin's effects on anemia-related symptoms.
                     We conclude that epoetin reduces the odds of transfusion for cancer patients undergoing therapy. Evidence is insufficient
                     to determine whether initiating epoetin earlier spares more patients from transfusion or results in better quality of life
                     than waiting until hemoglobin concentrations decline to nearly 10 g/dL. 
                  </p>
                  
               </div>
               <p id="p-2">Erythropoietin is an endogenous hormone, produced primarily in the kidney, which participates in regulating erythropoiesis
                  <em>(</em><a id="xref-ref-1-1" class="xref-bibr" href="#ref-1"><em>1</em></a><em>–</em><a id="xref-ref-3-1" class="xref-bibr" href="#ref-3"><em>3</em></a><em>).</em> Two forms of recombinant human erythropoietin, known generically as “epoetin alfa” and “epoetin beta,” were developed in
                  the 1980s and were initially used to treat anemia associated with end-stage renal disease <em>(</em><a id="xref-ref-1-2" class="xref-bibr" href="#ref-1"><em>1</em></a><em>,</em><a id="xref-ref-4-1" class="xref-bibr" href="#ref-4"><em>4</em></a><em>,</em><a id="xref-ref-5-1" class="xref-bibr" href="#ref-5"><em>5</em></a><em>).</em> Anemia that commonly accompanies malignancies may result from changes in the production of or response to erythropoietin
                  caused by the cancer and/or its treatment <em>(</em><a id="xref-ref-6-1" class="xref-bibr" href="#ref-6"><em>6</em></a><em>–</em><a id="xref-ref-8-1" class="xref-bibr" href="#ref-8"><em>8</em></a><em>).</em> Clinical trials have shown that epoetin increases red blood cell (RBC) counts and hemoglobin concentrations in many patients
                  with anemia caused by cancer therapy [<em>see (</em><a id="xref-ref-6-2" class="xref-bibr" href="#ref-6"><em>6</em></a><em>–</em><a id="xref-ref-10-1" class="xref-bibr" href="#ref-10"><em>10</em></a><em>)</em> for recent reviews].
               </p>
               <p id="p-3">RBC transfusion has long been the primary treatment of severe or life-threatening anemia, operationally defined by the National
                  Cancer Institute-sponsored Cooperative Oncology Groups as hemoglobin concentrations of less than 8.0 g/dL <em>(</em><a id="xref-ref-11-1" class="xref-bibr" href="#ref-11"><em>11</em></a><em>).</em> Transfusion, however, is used cautiously in the treatment of moderate (8.0–10.0 g/dL) and mild (10.0 g/dL to just below normal
                  limits) anemia, because of the risks associated with exposure to allogeneic blood products <em>(</em><a id="xref-ref-7-1" class="xref-bibr" href="#ref-7"><em>7</em></a><em>,</em><a id="xref-ref-12-1" class="xref-bibr" href="#ref-12"><em>12</em></a><em>–</em><a id="xref-ref-14-1" class="xref-bibr" href="#ref-14"><em>14</em></a><em>)</em> and the concern with conserving the blood supply. With the availability of epoetin, moderate anemia can be treated and severe
                  anemia can be prevented. Epoetin also affords the opportunity to treat mild anemia, but it is uncertain whether there is clinical
                  benefit in doing so. Given the cost of epoetin treatment, estimated at $3700–$6600 per chemotherapy cycle <em>(</em><a id="xref-ref-15-1" class="xref-bibr" href="#ref-15"><em>15</em></a><em>–</em><a id="xref-ref-17-1" class="xref-bibr" href="#ref-17"><em>17</em></a><em>),</em> evidence on benefit is needed to make efficient use of epoetin in clinical care.
               </p>
               <p id="p-4">This systematic review and meta-analysis has two primary objectives. The first objective is to quantify the effects of epoetin
                  on transfusions and quality of life in patients with anemia primarily due to chemotherapy or radiation therapy. The outcomes
                  of epoetin treatment (plus transfusion if needed) are compared with the outcomes of transfusion alone. Combined results of
                  studies are reported for odds of transfusion, the only outcome where sufficient data were available, with sensitivity analysis
                  for parameters of study quality. The second objective is to determine whether outcomes are superior when epoetin is initiated
                  at higher thresholds of baseline hemoglobin concentration, i.e., as prophylaxis or when anemia is mild. This study is part
                  of a comprehensive systematic review on the outcomes of epoetin use in cancer-related anemia, which includes anemia primarily
                  due to treatment of malignancy, anemia primarily due to the underlying disease, and anemia due to myeloablative therapy before
                  stem cell transplantation <em>(</em><a id="xref-ref-18-1" class="xref-bibr" href="#ref-18"><em>18</em></a><em>).</em></p>
               <div class="section" id="sec-1">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-8" title="Results" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>M<span class="sc">ethods</span></h2>
                  
                  
                  <h3>Literature Search</h3>
                  
                  <p id="p-5">MEDLINE®, CANCERLIT®, and EMBASE® databases were searched for all articles published from January 1985 through December 1998
                     that included one of the following textwords (tw) or Medical Subject Headings (MeSH®) in their titles, abstracts, or keyword
                     lists: erythropoietin (MeSH®), epoetin alfa (MeSH®), erythropoietin (tw), epoetin (tw), Epogen (tw), Procrit (tw), Eprex (tw),
                     Marogen (tw), Recormon (tw), epo (tw), anemia/drug therapy (MeSH®; all subheadings), anemia/therapy (MeSH®; all subheadings),
                     or anemia/diet therapy (MeSH®; all subheadings). Search results were limited to articles on human subjects indexed under the
                     MeSH® terms “neoplasms” or “myelodysplastic syndromes” (all subheadings). There were no language restrictions.
                  </p>
                  
                  <p id="p-6">We also searched issues of <em>Current Contents on Diskette</em> and <em>Medscape Oncology</em> through October 30, 1999. Finally, we sought relevant abstracts presented at the 1999 and 2000 meetings of the American Society
                     of Clinical Oncology. A total of 2943 references were identified.
                  </p>
                  
                  
                  
                  <h3>Study Selection</h3>
                  
                  <p id="p-7">Study inclusion and exclusion criteria for this systematic review were identified prospectively. Eligibility was limited to
                     controlled trials because many characteristics of cancer patients (e.g., disease stage, tumor progression, and concurrent
                     treatments) could affect the outcomes of interest and confound interpretation of the effects of epoetin. Studies with nonrandomized
                     concurrent or historical controls were included if the reviewers could verify comparability of patients in the treatment and
                     control groups for age, malignancies, and baseline hemoglobin concentration.
                  </p>
                  
                  <p id="p-8">Studies were included if they enrolled patients with existing anemia due to cancer chemotherapy and/or radiotherapy or nonanemic
                     patients beginning a course of cancer therapy, if they enrolled 10 or more similarly treated evaluable patients in each arm,
                     and if they compared epoetin treatment (plus RBC transfusion when necessary) with RBC transfusion alone. In addition, included
                     studies reported at least one of the following outcomes: change in hemoglobin concentration from baseline to final value after
                     epoetin treatment, percentage of patients responding to epoetin, percentage of patients transfused, number of RBC units transfused
                     per patient, or quality of life. We also sought data on anemia-associated symptoms (e.g., shortness of breath, dyspnea on
                     exertion, and angina) or hospital utilization.
                  </p>
                  
                  <p id="p-9">Two reviewers (J. Seidenfeld and M. Piper) independently assessed study eligibility and resolved disagreements by consensus.
                     The comprehensive evidence report includes a list of all studies assessed for eligibility <em>(</em><a id="xref-ref-18-2" class="xref-bibr" href="#ref-18"><em>18</em></a><em>).</em> A thorough search identified no additional controlled trials published in a language other than English.
                  </p>
                  
                  
                  
                  <h3>Data Abstraction and Analysis</h3>
                  
                  <p id="p-10">Two reviewers (M. Piper and C. Flamm) independently abstracted data from each included study to separate copies of an electronic
                     database (Microsoft® Access 97). The completed databases were compared electronically, and disagreements were generally resolved
                     by reconciliation of an oversight. Reviewers estimated numerical values from figures for data reported only in graphs. Disagreements
                     were always less than 5%, and the consensus estimate was the midpoint.
                  </p>
                  
                  <p id="p-11">Abstracted data were analyzed to compare the outcomes of epoetin therapy with the outcomes of transfusion alone and to compare
                     the relative effects of epoetin treatment when different hemoglobin thresholds were used for initiating treatment. Included
                     studies were categorized by mean (if available) or median (six studies) hemoglobin concentration at enrollment: below normal
                     limits but 12 g/dL or higher, more than 10 g/dL but less than 12 g/dL, or 10 g/dL or less. For each baseline hemoglobin range,
                     we summarized hemoglobin changes [not shown here; <em>see (</em><a id="xref-ref-18-3" class="xref-bibr" href="#ref-18"><em>18</em></a><em>)</em>], transfusions, and health-related quality-of-life outcomes and qualitatively compared results. For each trial, we also calculated
                     the absolute differences between the treatment and control arms for each reported outcome.
                  </p>
                  
                  <p id="p-12">We evaluated the possibility that differences in the route, dose, dosing regimen, and duration with which epoetin was administered
                     might confound interpretation of the evidence. Limited space prevents inclusion of the analysis that convinced us that this
                     possibility was unlikely. We also looked for but did not find sufficient evidence to identify reliable predictors of hematologic
                     responses to epoetin. Interested readers are referred to the comprehensive evidence report <em>(</em><a id="xref-ref-18-4" class="xref-bibr" href="#ref-18"><em>18</em></a><em>)</em> for detailed information on these issues.
                  </p>
                  
                  
                  
                  <h3>Study Quality</h3>
                  
                  <p id="p-13">Our study selection criteria served as an initial quality screen and were designed to incorporate generally accepted quality
                     criteria <em>(</em><a id="xref-ref-19-1" class="xref-bibr" href="#ref-19"><em>19</em></a><em>).</em> In addition, we identified a subset of studies with a lower potential for biased results, using quality domains that have
                     been tested in empirical studies <em>(</em><a id="xref-ref-20-1" class="xref-bibr" href="#ref-20"><em>20</em></a><em>–</em><a id="xref-ref-22-1" class="xref-bibr" href="#ref-22"><em>22</em></a><em>).</em> Those in the subset, referred to as “higher quality studies” for the remainder of this review, were used for sensitivity
                     analysis, comparing their results with those from remaining studies, hereinafter referred to as “lower quality studies.” For
                     sensitivity analysis, we selected as higher quality those randomized, controlled trials that were double-blinded <em>(</em><a id="xref-ref-23-1" class="xref-bibr" href="#ref-23"><em>23</em></a><em>)</em> and also minimized exclusion bias. Double-blinding was emphasized, since knowledge of assigned treatment might alter investigators'
                     transfusion orders. We considered exclusion bias to be minimized when a study 1) reported intent-to-treat analysis or 2) excluded
                     fewer than 10% of subjects from analysis, and the ratio of subjects excluded from each arm was less than 2 : 1. We also assessed
                     studies for concealment of allocation to treatment arms, but we found this to be prone to reporting bias because most included
                     studies were published before the CONSORT (i.e., Consolidated Standards of Reporting Trials) statement <em>(</em><a id="xref-ref-24-1" class="xref-bibr" href="#ref-24"><em>24</em></a><em>).</em></p>
                  
                  
                  
                  <h3>Special Issues for Quality of Studies Reporting Quality-of-Life Outcomes</h3>
                  
                  <p id="p-14">Rigorous control of other factors that may also affect quality of life (e.g., tumor stage and progression, effects of cancer
                     therapy, and changes in cancer therapy regimen) is necessary to demonstrate that epoetin treatment changes quality of life
                     <em>(</em><a id="xref-ref-25-1" class="xref-bibr" href="#ref-25"><em>25</em></a><em>).</em> Uncontrolled studies <em>(</em><a id="xref-ref-26-1" class="xref-bibr" href="#ref-26"><em>26</em></a><em>–</em><a id="xref-ref-28-1" class="xref-bibr" href="#ref-28"><em>28</em></a><em>)</em> and comparisons to historical or prospective but nonrandomized control groups have examined quality of life; however, they
                     may suffer from selection bias and the inability to disentangle the effects of such confounding variables. Quality-of-life
                     results also can be affected by the validity of the quality-of-life instrument, how it is administered, and the interaction
                     between the physician and patient.
                  </p>
                  
                  <p id="p-15">We examined trials that assessed quality of life for design features related to the administration of quality-of-life instruments
                     and the analysis and interpretation of results. An extensive literature over the past decade has identified key methodologic
                     features needed in studies that measure quality of life <em>(</em><a id="xref-ref-29-1" class="xref-bibr" href="#ref-29"><em>29</em></a><em>–</em><a id="xref-ref-31-1" class="xref-bibr" href="#ref-31"><em>31</em></a><em>).</em> On the basis of this literature, the U.S. Food and Drug Administration has outlined guidelines for conducting randomized,
                     controlled trials that assess quality-of-life end points for oncology drugs <em>(</em><a id="xref-ref-32-1" class="xref-bibr" href="#ref-32"><em>32</em></a><em>,</em><a id="xref-ref-33-1" class="xref-bibr" href="#ref-33"><em>33</em></a><em>).</em> These features include the following: use of validated instruments; double-blinding or blinding of personnel administering
                     the quality-of-life questionnaires; prospective identification of the key outcomes, critical time points, and minimum differences
                     in scores to be considered clinically significant; and a detailed plan for preventing missing data, investigating the pattern
                     of missing data, and addressing missing data in the analysis.
                  </p>
                  
                  
                  
                  <h3>Meta-analysis</h3>
                  
                  <p id="p-16">Reduction in the risk of RBC transfusion was the only outcome for which adequate data were available for meta-analysis. Because
                     epoetin affects anemia rather than malignancy, we combined data from epoetin trials on patients affected with different malignancies
                     and receiving different therapies. We limited inclusion in the meta-analysis to randomized, controlled studies in which epoetin
                     was administered subcutaneously and numbers or percentages of patients transfused were reported. Results from each study were
                     summarized as a ratio of the odds of transfusion for epoetin-treated patients to the odds for control patients.
                  </p>
                  
                  <p id="p-17">Protocols of the randomized trials included in the meta-analysis varied with respect to epoetin dose, baseline hemoglobin
                     concentration, duration of follow-up, and study quality. Therefore, we used a random-effects model [the Empirical Bayes estimator
                     <em>(</em><a id="xref-ref-34-1" class="xref-bibr" href="#ref-34"><em>34</em></a><em>),</em> calculated with FAST*PRO software <em>(</em><a id="xref-ref-35-1" class="xref-bibr" href="#ref-35"><em>35</em></a><em>)</em>]. We tested for heterogeneity according to the procedure of DerSimonian and Laird <em>(</em><a id="xref-ref-36-1" class="xref-bibr" href="#ref-36"><em>36</em></a><em>).</em></p>
                  
                  <p id="p-18">To adjust for other variables (e.g., epoetin dose) that might influence the effect of treatment, we fitted a multiple logistic
                     regression model with a random- effects term using Egret software <em>(</em><a id="xref-ref-37-1" class="xref-bibr" href="#ref-37"><em>37</em></a><em>).</em> The model can be written as<span class="disp-formula" id="disp-formula-1"><img class="math tex" alt="Formula" src="1204/embed/tex-math-1.gif" /></span>where <em>p<sub>ik</sub></em>(<em>x</em>) is the probability of a transfusion event for the <em>k</em><sup>th</sup> arm of the <em>i</em><sup>th</sup> study, α<sub><em>j</em></sub> is a term for the log-odds of transfusion in the control group of the <em>i</em><sup>th</sup> study, <em>x<sub>ij</sub></em> = 1 if <em>i</em> equals <em>j</em> and <em>x<sub>ij</sub></em> equals 0 otherwise (i.e., <em>x<sub>ij</sub></em> matches the correct value of α for each study). β is the logistic regression coefficient for the effect of the epoetin dose
                     in the <em>i</em><sup>th</sup> study, <em>x</em><sub><em>i,m</em>+1</sub> is the actual epoetin dose for the <em>k</em><sup>th</sup> arm of the <em>i</em><sup>th</sup> study, ε is a standard normal random variable, and θ<sup>2</sup> is the random-effects variation. The terms are estimated with the use of maximum likelihood methods.
                  </p>
                  
                  <p id="p-19">In the analysis, each study was treated exactly as it was designed—a three-arm study contributed three records. Each study
                     had its own dummy variables to allow for study differences, and the effects of different doses were modeled with the use of
                     appropriate regression terms. Thus, the assumption of independence was not violated. This analysis is described in detail
                     by Hasselblad <em>(</em><a id="xref-ref-38-1" class="xref-bibr" href="#ref-38"><em>38</em></a><em>).</em></p>
                  
                  <p id="p-20">The number of patients who would need to be treated with epoetin to spare one patient from receiving a transfusion (NNT) was
                     derived from the reciprocal of the absolute risk reduction <em>(</em><a id="xref-ref-39-1" class="xref-bibr" href="#ref-39"><em>39</em></a><em>).</em> Absolute risk for the controls was determined by the estimation of the odds of transfusion for the combined control study
                     arms (from studies with a known follow-up duration) with the use of a logistic normal model and the point estimate for a 12-week
                     follow-up duration <em>(</em><a id="xref-ref-38-2" class="xref-bibr" href="#ref-38"><em>38</em></a><em>).</em> The estimate of the odds was converted to the corresponding probability. From this and the summary odds ratio, the probability
                     of odds of transfusion for the combined epoetin-treated study arms was calculated.
                  </p>
                  
                  
               </div>
               <div class="section" id="sec-8">
                  <div class="section-nav"><a href="#sec-1" title="Methods" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-20" title="Discussion" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>R<span class="sc">esults</span></h2>
                  
                  
                  <h3>Overview of the Evidence</h3>
                  
                  <p id="p-21">Twenty-two controlled trials <em>(</em><a id="xref-ref-40-1" class="xref-bibr" href="#ref-40"><em>40</em></a><em>–</em><a id="xref-ref-61-1" class="xref-bibr" href="#ref-61"><em>61</em></a><em>)</em> met the study selection criteria of this systematic review. The total enrollment was 1927 patients, of whom 1838 (95%) were
                     evaluable. Unless otherwise specified, data on patient numbers refer to enrollment. The mean hemoglobin concentration at enrollment
                     ranged from 8.6 to 13.0 g/dL in these studies. Of the 22 studies, 17 <em>(</em><a id="xref-ref-40-2" class="xref-bibr" href="#ref-40"><em>40</em></a><em>–</em><a id="xref-ref-47-1" class="xref-bibr" href="#ref-47"><em>47</em></a><em>,</em><a id="xref-ref-49-1" class="xref-bibr" href="#ref-49"><em>49</em></a><em>–</em><a id="xref-ref-53-1" class="xref-bibr" href="#ref-53"><em>53</em></a><em>,</em><a id="xref-ref-55-1" class="xref-bibr" href="#ref-55"><em>55</em></a>, <a id="xref-ref-57-1" class="xref-bibr" href="#ref-57"><em>57</em></a><em>,</em><a id="xref-ref-60-1" class="xref-bibr" href="#ref-60"><em>60</em></a><em>,</em><a id="xref-ref-61-2" class="xref-bibr" href="#ref-61"><em>61</em></a><em>)</em> reported at least one transfusion outcome (n = 1703), of which 12 [n = 1390 evaluable; <em>(</em><a id="xref-ref-40-3" class="xref-bibr" href="#ref-40"><em>40</em></a><em>–</em><a id="xref-ref-44-1" class="xref-bibr" href="#ref-44"><em>44</em></a><em>,</em><a id="xref-ref-51-1" class="xref-bibr" href="#ref-51"><em>51</em></a><em>–</em><a id="xref-ref-53-2" class="xref-bibr" href="#ref-53"><em>53</em></a><em>,</em><a id="xref-ref-55-2" class="xref-bibr" href="#ref-55"><em>55</em></a><em>,</em><a id="xref-ref-57-2" class="xref-bibr" href="#ref-57"><em>57</em></a><em>,</em><a id="xref-ref-60-2" class="xref-bibr" href="#ref-60"><em>60</em></a><em>,</em><a id="xref-ref-61-3" class="xref-bibr" href="#ref-61"><em>61</em></a><em>)</em>] met selection criteria for the meta-analysis. Six [n = 829; <em>(</em><a id="xref-ref-40-4" class="xref-bibr" href="#ref-40"><em>40</em></a><em>–</em><a id="xref-ref-45-1" class="xref-bibr" href="#ref-45"><em>45</em></a><em>)</em>] of the 17 trials met our definition of higher quality, but one [n = 30; <em>(</em><a id="xref-ref-45-2" class="xref-bibr" href="#ref-45"><em>45</em></a><em>)</em>] was excluded from the meta-analysis because epoetin was administered intravenously.
                  </p>
                  
                  <p id="p-22">Table 1<a id="xref-table-wrap-1-1 class='xref-arrow-link'"><span>⇔</span></a> lists the number of trials (and their combined enrollment) that used different study designs, studied different patient populations,
                     and reported the outcomes of interest. One trial [Quirt et al. <em>(</em><a id="xref-ref-51-2" class="xref-bibr" href="#ref-51"><em>51</em></a><em>);</em> n = 56] was published only as an abstract. A second trial [Littlewood et al. <em>(</em><a id="xref-ref-44-2" class="xref-bibr" href="#ref-44"><em>44</em></a><em>);</em> n = 375)<a id="xref-fn-1-1" class="xref-fn" href="#fn-1"><sup>1</sup></a>] was available only as an abstract when the systematic review was conducted, but it was published in full as this review
                     went to press.
                  </p>
                  <div class="table pos-float" id="T1">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="1204/T1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1204/T1.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label">
                           <strong>Table 1. </strong>
                           </span> 
                        
                        <p id="p-60" class="first-child">Characteristics and enrollment of 22 included studies*</p>
                        
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-23">Most trials had small sample sizes, lacking statistical power to detect a difference between study arms (Table 1<a id="xref-table-wrap-1-2 class='xref-arrow-link'"><span>⇔</span></a>). We calculated that detection of a 50% reduction in the percentage of patients transfused at 80% power would require 58
                     patients per study arm. Only four trials <em>(</em><a id="xref-ref-40-5" class="xref-bibr" href="#ref-40"><em>40</em></a><em>,</em><a id="xref-ref-41-1" class="xref-bibr" href="#ref-41"><em>41</em></a><em>,</em><a id="xref-ref-44-3" class="xref-bibr" href="#ref-44"><em>44</em></a><em>,</em><a id="xref-ref-52-1" class="xref-bibr" href="#ref-52"><em>52</em></a><em>)</em> enrolled more than 100 patients and had 50 or more patients in each study arm. This, together with the fact that only six
                     trials <em>(</em><a id="xref-ref-42-1" class="xref-bibr" href="#ref-42"><em>42</em></a><em>–</em><a id="xref-ref-44-4" class="xref-bibr" href="#ref-44"><em>44</em></a><em>,</em><a id="xref-ref-49-2" class="xref-bibr" href="#ref-49"><em>49</em></a><em>,</em><a id="xref-ref-55-3" class="xref-bibr" href="#ref-55"><em>55</em></a><em>,</em><a id="xref-ref-57-3" class="xref-bibr" href="#ref-57"><em>57</em></a><em>)</em> reported a statistically significant reduction in percentage transfused for the epoetin arms, makes meta-analysis useful
                     to estimate the magnitude of epoetin's effect.
                  </p>
                  
                  <p id="p-24">No trials reported on symptoms of anemia (including shortness of breath, dyspnea on exertion, or angina) or number of days
                     in hospital. The only trial that reported changes in performance status <em>(</em><a id="xref-ref-49-3" class="xref-bibr" href="#ref-49"><em>49</em></a><em>)</em> used the Karnofsky performance scale as a surrogate for quality of life.
                  </p>
                  
                  
                  <h4>Study quality.</h4>
                  
                  <p id="p-25"> Study selection criteria eliminated single-arm trials and ensured a basic level of study quality for all included studies.
                     Only five trials <em>(</em><a id="xref-ref-40-6" class="xref-bibr" href="#ref-40"><em>40</em></a><em>–</em><a id="xref-ref-43-1" class="xref-bibr" href="#ref-43"><em>43</em></a><em>,</em><a id="xref-ref-55-4" class="xref-bibr" href="#ref-55"><em>55</em></a><em>)</em> reported all four hematologic and transfusion outcomes of interest for each study arm. Furthermore, trials did not consistently
                     report tests of statistical significance for differences in baseline characteristics or outcomes between epoetin and control
                     arms. Although 10 trials prospectively specified a transfusion trigger <em>(</em><a id="xref-ref-42-2" class="xref-bibr" href="#ref-42"><em>42</em></a><em>,</em><a id="xref-ref-43-2" class="xref-bibr" href="#ref-43"><em>43</em></a><em>,</em><a id="xref-ref-45-3" class="xref-bibr" href="#ref-45"><em>45</em></a><em>,</em><a id="xref-ref-46-1" class="xref-bibr" href="#ref-46"><em>46</em></a>, <a id="xref-ref-47-2" class="xref-bibr" href="#ref-47"><em>47</em></a><em>,</em><a id="xref-ref-49-4" class="xref-bibr" href="#ref-49"><em>49</em></a><em>,</em><a id="xref-ref-50-1" class="xref-bibr" href="#ref-50"><em>50</em></a><em>,</em><a id="xref-ref-53-3" class="xref-bibr" href="#ref-53"><em>53</em></a><em>,</em><a id="xref-ref-57-4" class="xref-bibr" href="#ref-57"><em>57</em></a><em>,</em><a id="xref-ref-60-3" class="xref-bibr" href="#ref-60"><em>60</em></a><em>),</em> only four <em>(</em><a id="xref-ref-40-7" class="xref-bibr" href="#ref-40"><em>40</em></a><em>,</em><a id="xref-ref-41-2" class="xref-bibr" href="#ref-41"><em>41</em></a><em>,</em><a id="xref-ref-55-5" class="xref-bibr" href="#ref-55"><em>55</em></a><em>,</em><a id="xref-ref-61-4" class="xref-bibr" href="#ref-61"><em>61</em></a><em>)</em> reported the mean hemoglobin concentration at transfusion for each arm, leaving open the possibility that transfusion practices
                     may have differed between arms in the other 18 studies.
                  </p>
                  
                  <p id="p-26">Six trials <em>(</em><a id="xref-ref-40-8" class="xref-bibr" href="#ref-40"><em>40</em></a><em>–</em><a id="xref-ref-45-4" class="xref-bibr" href="#ref-45"><em>45</em></a><em>)</em> were identified as higher quality for sensitivity analysis. The seventh randomized, placebo-controlled, double-blinded trial
                     <em>(</em><a id="xref-ref-46-2" class="xref-bibr" href="#ref-46"><em>46</em></a><em>)</em> did not meet the criterion for percentage of patients excluded from analysis. Five of the higher quality studies <em>(</em><a id="xref-ref-40-9" class="xref-bibr" href="#ref-40"><em>40</em></a><em>–</em><a id="xref-ref-44-5" class="xref-bibr" href="#ref-44"><em>44</em></a><em>)</em> enrolled groups with a mean baseline hemoglobin concentration of 10 g/dL or less. In the remaining higher quality trial <em>(</em><a id="xref-ref-45-5" class="xref-bibr" href="#ref-45"><em>45</em></a><em>),</em> the mean baseline hemoglobin concentration was greater than 10 g/dL but less than 12 g/dL; however, this trial was excluded
                     from the meta-analysis because epoetin was administered intravenously.
                  </p>
                  
                  
                  
                  <h4>Study quality for quality-of-life outcomes.</h4>
                  
                  <p id="p-27"> Nine studies <em>(</em><a id="xref-ref-40-10" class="xref-bibr" href="#ref-40"><em>40</em></a><em>,</em><a id="xref-ref-41-3" class="xref-bibr" href="#ref-41"><em>41</em></a><em>,</em><a id="xref-ref-43-3" class="xref-bibr" href="#ref-43"><em>43</em></a><em>,</em><a id="xref-ref-44-6" class="xref-bibr" href="#ref-44"><em>44</em></a><em>,</em><a id="xref-ref-49-5" class="xref-bibr" href="#ref-49"><em>49</em></a><em>,</em><a id="xref-ref-54-1" class="xref-bibr" href="#ref-54"><em>54</em></a><em>,</em><a id="xref-ref-55-6" class="xref-bibr" href="#ref-55"><em>55</em></a><em>,</em><a id="xref-ref-60-4" class="xref-bibr" href="#ref-60"><em>60</em></a><em>,</em><a id="xref-ref-61-5" class="xref-bibr" href="#ref-61"><em>61</em></a><em>)</em> reported quality-of-life outcomes (n = 851 evaluable), but two of these studies [n = 216 evaluable; <em>(</em><a id="xref-ref-40-11" class="xref-bibr" href="#ref-40"><em>40</em></a><em>,</em><a id="xref-ref-55-7" class="xref-bibr" href="#ref-55"><em>55</em></a><em>)</em>] reported only within-arm changes and did not compare differences between arms. None of the studies reported the features
                     considered important for minimizing bias in measuring quality of life <em>(</em><a id="xref-ref-25-2" class="xref-bibr" href="#ref-25"><em>25</em></a><em>,</em><a id="xref-ref-29-2" class="xref-bibr" href="#ref-29"><em>29</em></a><em>–</em><a id="xref-ref-33-2" class="xref-bibr" href="#ref-33"><em>33</em></a><em>).</em> Linear Analogue Self-Assessment (LASA) scales were the most frequently used quality-of-life instruments, reported in seven
                     trials overall <em>(</em><a id="xref-ref-40-12" class="xref-bibr" href="#ref-40"><em>40</em></a><em>,</em><a id="xref-ref-41-4" class="xref-bibr" href="#ref-41"><em>41</em></a><em>,</em><a id="xref-ref-43-4" class="xref-bibr" href="#ref-43"><em>43</em></a><em>,</em><a id="xref-ref-44-7" class="xref-bibr" href="#ref-44"><em>44</em></a><em>,</em><a id="xref-ref-54-2" class="xref-bibr" href="#ref-54"><em>54</em></a><em>,</em><a id="xref-ref-55-8" class="xref-bibr" href="#ref-55"><em>55</em></a><em>,</em><a id="xref-ref-61-6" class="xref-bibr" href="#ref-61"><em>61</em></a><em>)</em> and in five <em>(</em><a id="xref-ref-41-5" class="xref-bibr" href="#ref-41"><em>41</em></a><em>,</em><a id="xref-ref-43-5" class="xref-bibr" href="#ref-43"><em>43</em></a><em>,</em><a id="xref-ref-44-8" class="xref-bibr" href="#ref-44"><em>44</em></a><em>,</em><a id="xref-ref-54-3" class="xref-bibr" href="#ref-54"><em>54</em></a><em>,</em><a id="xref-ref-61-7" class="xref-bibr" href="#ref-61"><em>61</em></a><em>)</em> of seven that compared differences between treatment arms. The LASA scale questionnaire items reported most frequently in
                     these studies were overall quality of life, energy level, and daily activities. Note that the overall quality-of-life score
                     is not a summary score, and it is only one of three or more separate dimensions. Furthermore, results with different LASA
                     scales cannot be combined, since each is a unidimensional instrument. Only one trial <em>(</em><a id="xref-ref-44-9" class="xref-bibr" href="#ref-44"><em>44</em></a><em>)</em> used the Functional Assessment of Cancer Therapy—anemia (FACT-An) instrument <em>(</em><a id="xref-ref-62-1" class="xref-bibr" href="#ref-62"><em>62</em></a><em>,</em><a id="xref-ref-63-1" class="xref-bibr" href="#ref-63"><em>63</em></a><em>)</em> and LASA scales. Of the two remaining trials, one <em>(</em><a id="xref-ref-49-6" class="xref-bibr" href="#ref-49"><em>49</em></a><em>)</em> used Karnofsky performance scales and one <em>(</em><a id="xref-ref-60-5" class="xref-bibr" href="#ref-60"><em>60</em></a><em>)</em> used the Psychological Distress Inventory.
                  </p>
                  
                  <p id="p-28">Four <em>(</em><a id="xref-ref-40-13" class="xref-bibr" href="#ref-40"><em>40</em></a><em>,</em><a id="xref-ref-41-6" class="xref-bibr" href="#ref-41"><em>41</em></a><em>,</em><a id="xref-ref-43-6" class="xref-bibr" href="#ref-43"><em>43</em></a><em>,</em><a id="xref-ref-44-10" class="xref-bibr" href="#ref-44"><em>44</em></a><em>)</em> of nine studies that reported quality-of-life outcomes were selected as higher quality for sensitivity analysis of transfusion
                     outcomes. But three <em>(</em><a id="xref-ref-40-14" class="xref-bibr" href="#ref-40"><em>40</em></a><em>,</em><a id="xref-ref-41-7" class="xref-bibr" href="#ref-41"><em>41</em></a><em>,</em><a id="xref-ref-44-11" class="xref-bibr" href="#ref-44"><em>44</em></a><em>)</em> of the four exceeded our threshold for excluding patients from quality-of-life outcomes, with 10%–40% of enrolled patients
                     not evaluable. Such missing data may not be distributed randomly and may be independently associated with quality of life.
                     For example, patients who are severely ill may be more likely to have missing quality-of-life data after baseline, potentially
                     biasing results.
                  </p>
                  
                  
                  
                  
                  <h3>Epoetin Compared With Transfusion</h3>
                  
                  <p id="p-29">Table 2<a id="xref-table-wrap-2-1 class='xref-arrow-link'"><span>⇔</span></a> summarizes the ranges of results reported for transfusion outcomes: the percentage of patients transfused and the number
                     of RBC units transfused per patient (normalized to 4 weeks whenever possible). For results reported by each included study,
                     <em>see</em> the comprehensive evidence report <em>(</em><a id="xref-ref-18-5" class="xref-bibr" href="#ref-18"><em>18</em></a><em>).</em> Table 3<a id="xref-table-wrap-3-1 class='xref-arrow-link'"><span>⇔</span></a> and Figs. 1 and 2<a id="xref-fig-1-1 class='xref-arrow-link'"><span>⇔</span></a><a id="xref-fig-2-1 class='xref-arrow-link'"><span>⇔</span></a> present combined results for percentage of patients transfused. Table 4<a id="xref-table-wrap-4-1 class='xref-arrow-link'"><span>⇔</span></a> summarizes results from studies reporting quality-of-life outcomes.
                  </p>
                  <div class="table pos-float" id="T2">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="1204/T2.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1204/T2.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label">
                           <strong>Table 2. </strong>
                           </span> 
                        
                        <p id="p-61" class="first-child">Range of results for transfusion outcomes*</p>
                        
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  <div class="table pos-float" id="T3">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="1204/T3.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1204/T3.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label">
                           <strong>Table 3. </strong>
                           </span> 
                        
                        <p id="p-62" class="first-child">Results of meta-analysis on the risk of transfusion*</p>
                        
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  <div class="table pos-float" id="T4">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="1204/T4.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1204/T4.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label">
                           <strong>Table 4. </strong>
                           </span> 
                        
                        <p id="p-63" class="first-child">Quality-of-life (QoL) outcomes for studies grouped by mean baseline hemoglobin (Hb) concentrations: comparisons between control
                           and epoetin-treated study arms*
                        </p>
                        
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  <div id="F1" class="fig pos-float odd">
                     <div class="fig-inline"><a href="1204/F1.expansion.html"><img alt="  Fig. 1.  " src="1204/F1.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a href="1204/F1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1204/F1.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="/powerpoint/93/16/1204/F1">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label">
                           <strong>Fig. 1. </strong>
                           </span> 
                        
                        <p id="p-64" class="first-child">Effect of epoetin (EPO) on the odds of transfusion in patients with anemia due to cancer therapy.</p>
                        
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  <div id="F2" class="fig pos-float odd">
                     <div class="fig-inline"><a href="1204/F2.expansion.html"><img alt="  Fig. 2.  " src="1204/F2.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a href="1204/F2.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1204/F2.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="/powerpoint/93/16/1204/F2">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label">
                           <strong>Fig. 2. </strong>
                           </span> 
                        
                        <p id="p-65" class="first-child">Effect of study quality on the odds ratio of transfusion.</p>
                        
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  
                  <h4>Transfusion outcomes.</h4>
                  
                  <p id="p-30"> Fourteen trials on adults [n = 1595; <em>(</em><a id="xref-ref-40-15" class="xref-bibr" href="#ref-40"><em>40</em></a><em>–</em><a id="xref-ref-45-6" class="xref-bibr" href="#ref-45"><em>45</em></a><em>,</em><a id="xref-ref-47-3" class="xref-bibr" href="#ref-47"><em>47</em></a><em>,</em><a id="xref-ref-50-2" class="xref-bibr" href="#ref-50"><em>50</em></a><em>–</em><a id="xref-ref-53-4" class="xref-bibr" href="#ref-53"><em>53</em></a><em>,</em><a id="xref-ref-55-9" class="xref-bibr" href="#ref-55"><em>55</em></a><em>,</em><a id="xref-ref-60-6" class="xref-bibr" href="#ref-60"><em>60</em></a><em>,</em><a id="xref-ref-61-8" class="xref-bibr" href="#ref-61"><em>61</em></a><em>)</em>] reported the percentage of patients transfused, and all found that fewer were transfused in the epoetin arms (Table 2<a id="xref-table-wrap-2-2 class='xref-arrow-link'"><span>⇔</span></a>). The range of differences in the percentage of patients transfused was approximately 7%–47%. The differences were statistically
                     significant in six trials <em>(</em><a id="xref-ref-42-3" class="xref-bibr" href="#ref-42"><em>42</em></a><em>–</em><a id="xref-ref-44-12" class="xref-bibr" href="#ref-44"><em>44</em></a><em>,</em><a id="xref-ref-52-2" class="xref-bibr" href="#ref-52"><em>52</em></a><em>,</em><a id="xref-ref-53-5" class="xref-bibr" href="#ref-53"><em>53</em></a><em>,</em><a id="xref-ref-55-10" class="xref-bibr" href="#ref-55"><em>55</em></a><em>).</em> Nine trials <em>(</em><a id="xref-ref-40-16" class="xref-bibr" href="#ref-40"><em>40</em></a><em>,</em><a id="xref-ref-42-4" class="xref-bibr" href="#ref-42"><em>42</em></a><em>,</em><a id="xref-ref-43-7" class="xref-bibr" href="#ref-43"><em>43</em></a><em>,</em><a id="xref-ref-45-7" class="xref-bibr" href="#ref-45"><em>45</em></a><em>,</em><a id="xref-ref-51-3" class="xref-bibr" href="#ref-51"><em>51</em></a><em>–</em><a id="xref-ref-53-6" class="xref-bibr" href="#ref-53"><em>53</em></a><em>,</em><a id="xref-ref-55-11" class="xref-bibr" href="#ref-55"><em>55</em></a><em>,</em><a id="xref-ref-61-9" class="xref-bibr" href="#ref-61"><em>61</em></a><em>)</em> also found that patients in the epoetin arm required fewer RBC units; the differences were statistically significant in only
                     four of the trials <em>(</em><a id="xref-ref-42-5" class="xref-bibr" href="#ref-42"><em>42</em></a><em>,</em><a id="xref-ref-45-8" class="xref-bibr" href="#ref-45"><em>45</em></a><em>,</em><a id="xref-ref-52-3" class="xref-bibr" href="#ref-52"><em>52</em></a><em>,</em><a id="xref-ref-55-12" class="xref-bibr" href="#ref-55"><em>55</em></a><em>).</em> The range of differences for RBC units transfused per patient per 4 weeks was 0–1.3.
                  </p>
                  
                  <p id="p-31">Of three pediatric trials (n = 108), two trials <em>(</em><a id="xref-ref-46-3" class="xref-bibr" href="#ref-46"><em>46</em></a><em>,</em><a id="xref-ref-57-5" class="xref-bibr" href="#ref-57"><em>57</em></a><em>)</em> reported that one transfusion outcome statistically significantly favored the epoetin arm and one trial <em>(</em><a id="xref-ref-49-7" class="xref-bibr" href="#ref-49"><em>49</em></a><em>)</em> reported that the difference was statistically significant for both outcomes. The range of differences between epoetin and
                     control arms for percentage of patients transfused was 10%–80%. The differences for RBC units transfused per patient per 4
                     weeks were 1.1 and 2.2 units.
                  </p>
                  
                  
                  
                  <h4>Combined odds of transfusion.</h4>
                  
                  <p id="p-32"> To provide a quantitative summary estimate of the effects of epoetin, we conducted a meta-analysis of the odds of transfusion.
                     All randomized trials in which epoetin was administered subcutaneously and the number or the percentage of patients transfused
                     was reported were eligible for meta-analysis. Twelve trials reporting on 1390 evaluable patients are included in the meta-analysis;
                     this number constitutes 72% of all patients enrolled in the 22 studies included in this systematic review. Two otherwise eligible
                     trials [n = 49 evaluable; <em>(</em><a id="xref-ref-45-9" class="xref-bibr" href="#ref-45"><em>45</em></a><em>,</em><a id="xref-ref-46-4" class="xref-bibr" href="#ref-46"><em>46</em></a><em>)</em>] were excluded because epoetin was administered intravenously; a preliminary analysis showed that the intravenous studies
                     had little effect on the summary estimate.
                  </p>
                  
                  <p id="p-33">A test for homogeneity <em>(</em><a id="xref-ref-36-2" class="xref-bibr" href="#ref-36"><em>36</em></a><em>)</em> among the 12 randomized trials with subcutaneous administration <em>(</em><a id="xref-ref-40-17" class="xref-bibr" href="#ref-40"><em>40</em></a><em>–</em><a id="xref-ref-44-13" class="xref-bibr" href="#ref-44"><em>44</em></a><em>,</em><a id="xref-ref-51-4" class="xref-bibr" href="#ref-51"><em>51</em></a><em>–</em><a id="xref-ref-53-7" class="xref-bibr" href="#ref-53"><em>53</em></a><em>,</em><a id="xref-ref-55-13" class="xref-bibr" href="#ref-55"><em>55</em></a><em>,</em><a id="xref-ref-57-6" class="xref-bibr" href="#ref-57"><em>57</em></a><em>,</em><a id="xref-ref-60-7" class="xref-bibr" href="#ref-60"><em>60</em></a><em>,</em><a id="xref-ref-61-10" class="xref-bibr" href="#ref-61"><em>61</em></a><em>)</em> indicated some degree of heterogeneity (chi-square of 17.3 for 11 <em>df; P</em> = .099). Meta-analysis using an empirical Bayesian random-effects model <em>(</em><a id="xref-ref-34-2" class="xref-bibr" href="#ref-34"><em>34</em></a><em>,</em><a id="xref-ref-35-2" class="xref-bibr" href="#ref-35"><em>35</em></a><em>)</em> resulted in a combined odds ratio of 0.38 (95% confidence interval [CI] = 0.28 to 0.51; Table 3<a id="xref-table-wrap-3-2 class='xref-arrow-link'"><span>⇔</span></a>; Fig. 1<a id="xref-fig-1-2 class='xref-arrow-link'"><span>⇔</span></a><em>).</em></p>
                  
                  <p id="p-34">A sensitivity analysis was performed with the use of only the five higher quality studies that administered epoetin subcutaneously
                     and that reported the number of patients transfused (Table 3<a id="xref-table-wrap-3-3 class='xref-arrow-link'"><span>⇔</span></a>; Fig. 2<a id="xref-fig-2-2 class='xref-arrow-link'"><span>⇔</span></a>). We estimated the epoetin effect on transfusion for the five higher quality studies [n = 771 evaluable; <em>(</em><a id="xref-ref-40-18" class="xref-bibr" href="#ref-40"><em>40</em></a><em>–</em><a id="xref-ref-44-14" class="xref-bibr" href="#ref-44"><em>44</em></a><em>)</em>] and separately for the seven remaining studies [n = 619 evaluable; <em>(</em><a id="xref-ref-51-5" class="xref-bibr" href="#ref-51"><em>51</em></a><em>–</em><a id="xref-ref-53-8" class="xref-bibr" href="#ref-53"><em>53</em></a><em>,</em><a id="xref-ref-55-14" class="xref-bibr" href="#ref-55"><em>55</em></a><em>,</em><a id="xref-ref-57-7" class="xref-bibr" href="#ref-57"><em>57</em></a><em>,</em><a id="xref-ref-60-8" class="xref-bibr" href="#ref-60"><em>60</em></a><em>,</em><a id="xref-ref-61-11" class="xref-bibr" href="#ref-61"><em>61</em></a><em>)</em>]. The results of this analysis are shown in Table 3<a id="xref-table-wrap-3-4 class='xref-arrow-link'"><span>⇔</span></a> and Fig. 2<a id="xref-fig-2-3 class='xref-arrow-link'"><span>⇔</span></a>. Higher quality studies showed a statistically significantly smaller effect of epoetin on the risk of transfusion (odds ratio
                     = 0.45; 95% CI = 0.33 to 0.62) than lower quality studies (odds ratio = 0.14; 95% CI = 0.060 to 0.31); 95% CIs for the odds
                     ratios do not overlap.
                  </p>
                  
                  <p id="p-35">To express the absolute effectiveness of epoetin, we also calculated the number of patients who would need to be treated to
                     prevent one patient from being transfused (NNT). The overall NNT for all studies in the meta-analysis was 4.4 (95% CI = 3.6
                     to 6.1; Table 3<a id="xref-table-wrap-3-5 class='xref-arrow-link'"><span>⇔</span></a>). Therefore, four to five patients would need to receive epoetin for one patient to avoid transfusion. The NNT for higher
                     quality and lower quality studies is 5.2 (95% CI = 3.8 to 8.4) and 2.6 (95% CI = 2.1 to 3.8), respectively. Thus, the higher
                     quality studies predict that one patient would avoid transfusion for every five to six patients treated with epoetin, whereas
                     the lower quality studies predict one for every two to three treated.
                  </p>
                  
                  
                  
                  <h4>Quality-of-life outcomes.</h4>
                  
                  <p id="p-36"> The strongest evidence is currently a randomized, controlled trial that enrolled patient populations with mean baseline hemoglobin
                     concentrations of 10 g/dL or less <em>(</em><a id="xref-ref-44-15" class="xref-bibr" href="#ref-44"><em>44</em></a><em>).</em> This trial (n = 375, with 359 evaluable for transfusion outcomes but 290–335 evaluable for quality-of-life outcomes) compared
                     the change in quality-of-life scores between control and epoetin-treated study arms from visual analog scales and from the
                     FACT-An and found positive, statistically significant differences (Table 4<a id="xref-table-wrap-4-2 class='xref-arrow-link'"><span>⇔</span></a>). Results from the Medical Outcomes Study Short Form-36 (SF-36) were in the same direction but not statistically significant.
                     However, key methodologic features for administering the quality-of-life instruments (<em>see</em> the “Methods” section) were not described. In addition, the minimum changes in quality-of-life scores considered to be clinically
                     significant were not defined prospectively or in the discussion of results.
                  </p>
                  
                  <p id="p-37">Of the eight other studies reporting quality-of-life outcomes <em>(</em><a id="xref-ref-40-19" class="xref-bibr" href="#ref-40"><em>40</em></a><em>,</em><a id="xref-ref-41-8" class="xref-bibr" href="#ref-41"><em>41</em></a><em>,</em><a id="xref-ref-43-8" class="xref-bibr" href="#ref-43"><em>43</em></a><em>,</em><a id="xref-ref-49-8" class="xref-bibr" href="#ref-49"><em>49</em></a><em>,</em><a id="xref-ref-54-4" class="xref-bibr" href="#ref-54"><em>54</em></a><em>,</em><a id="xref-ref-55-15" class="xref-bibr" href="#ref-55"><em>55</em></a><em>,</em><a id="xref-ref-60-9" class="xref-bibr" href="#ref-60"><em>60</em></a><em>,</em><a id="xref-ref-61-12" class="xref-bibr" href="#ref-61"><em>61</em></a><em>),</em> six <em>(</em><a id="xref-ref-41-9" class="xref-bibr" href="#ref-41"><em>41</em></a><em>,</em><a id="xref-ref-43-9" class="xref-bibr" href="#ref-43"><em>43</em></a><em>,</em><a id="xref-ref-49-9" class="xref-bibr" href="#ref-49"><em>49</em></a><em>,</em><a id="xref-ref-54-5" class="xref-bibr" href="#ref-54"><em>54</em></a><em>,</em><a id="xref-ref-60-10" class="xref-bibr" href="#ref-60"><em>60</em></a><em>,</em><a id="xref-ref-61-13" class="xref-bibr" href="#ref-61"><em>61</em></a><em>)</em> reported statistical comparisons between control and epoetin-treated study arms [Table 4<a id="xref-table-wrap-4-3 class='xref-arrow-link'"><span>⇔</span></a>; <em>see</em> the comprehensive evidence report <em>(</em><a id="xref-ref-18-6" class="xref-bibr" href="#ref-18"><em>18</em></a><em>)</em> for within-arm comparisons of baseline to final results]. Of these six, only one <em>(</em><a id="xref-ref-41-10" class="xref-bibr" href="#ref-41"><em>41</em></a><em>)</em> reported a statistically significant between-arm difference on a quality-of-life measure favoring epoetin. This study reported
                     statistically significantly improved results on an item that asked about overall quality of life with the use of a visual
                     analog scale but not on items that asked about energy level or daily activities (Table 4<a id="xref-table-wrap-4-4 class='xref-arrow-link'"><span>⇔</span></a>). Another study <em>(</em><a id="xref-ref-49-10" class="xref-bibr" href="#ref-49"><em>49</em></a><em>)</em> reported a statistically significant difference favoring epoetin with the use of the Karnofsky scale as a surrogate for quality
                     of life. Meta-analysis on quality-of-life outcomes was not possible, since the available studies used different instruments.
                  </p>
                  
                  
                  
                  
                  <h3>Relative Effects of Initiating Epoetin at Different Thresholds of Baseline Hemoglobin</h3>
                  
                  <p id="p-38">No trials directly compared the outcomes of initiating epoetin treatment at alternative hemoglobin thresholds. In addition,
                     no trials associated the outcomes of epoetin therapy with patients' baseline hemoglobin concentration. Thus, only inferences
                     based on indirect comparison are possible as to whether initiating epoetin at one or another hemoglobin threshold results
                     in superior outcomes.
                  </p>
                  
                  
                  <h4>Transfusion outcomes at different baseline hemoglobin ranges.</h4>
                  
                  <p id="p-39"> Data included in the comprehensive evidence report <em>(</em><a id="xref-ref-18-7" class="xref-bibr" href="#ref-18"><em>18</em></a><em>),</em> but not shown here, demonstrate that epoetin increased the percentage of patients with a hematologic response and increased
                     hemoglobin concentrations by approximately the same amount for groups in each range of mean baseline hemoglobin concentrations.
                     Here we report only on transfusion outcomes.
                  </p>
                  
                  <p id="p-40">Of six trials [n = 1026; <em>(</em><a id="xref-ref-40-20" class="xref-bibr" href="#ref-40"><em>40</em></a><em>–</em><a id="xref-ref-44-16" class="xref-bibr" href="#ref-44"><em>44</em></a><em>,</em><a id="xref-ref-52-4" class="xref-bibr" href="#ref-52"><em>52</em></a><em>)</em>] on adults with mean baseline hemoglobin concentrations of 10 g/dL or less and reporting the percentage of patients transfused,
                     four <em>(</em><a id="xref-ref-42-6" class="xref-bibr" href="#ref-42"><em>42</em></a><em>–</em><a id="xref-ref-44-17" class="xref-bibr" href="#ref-44"><em>44</em></a><em>,</em><a id="xref-ref-52-5" class="xref-bibr" href="#ref-52"><em>52</em></a><em>),</em> including three of the five higher quality studies, reported statistically significantly fewer patients transfused. Four
                     <em>(</em><a id="xref-ref-40-21" class="xref-bibr" href="#ref-40"><em>40</em></a><em>,</em><a id="xref-ref-42-7" class="xref-bibr" href="#ref-42"><em>42</em></a><em>,</em><a id="xref-ref-43-10" class="xref-bibr" href="#ref-43"><em>43</em></a>, <a id="xref-ref-52-6" class="xref-bibr" href="#ref-52"><em>52</em></a><em>)</em> of five reporting trials, including three <em>(</em><a id="xref-ref-40-22" class="xref-bibr" href="#ref-40"><em>40</em></a><em>,</em><a id="xref-ref-42-8" class="xref-bibr" href="#ref-42"><em>42</em></a><em>,</em><a id="xref-ref-43-11" class="xref-bibr" href="#ref-43"><em>43</em></a><em>)</em> of the higher quality studies, also found that patients required fewer RBC units, although the differences were statistically
                     significant in only two of the trials <em>(</em><a id="xref-ref-42-9" class="xref-bibr" href="#ref-42"><em>42</em></a><em>,</em><a id="xref-ref-52-7" class="xref-bibr" href="#ref-52"><em>52</em></a><em>).</em></p>
                  
                  <p id="p-41">In five trials [n = 347; <em>(</em><a id="xref-ref-45-10" class="xref-bibr" href="#ref-45"><em>45</em></a><em>,</em><a id="xref-ref-47-4" class="xref-bibr" href="#ref-47"><em>47</em></a><em>,</em><a id="xref-ref-50-3" class="xref-bibr" href="#ref-50"><em>50</em></a><em>,</em><a id="xref-ref-51-6" class="xref-bibr" href="#ref-51"><em>51</em></a><em>,</em><a id="xref-ref-53-9" class="xref-bibr" href="#ref-53"><em>53</em></a><em>)</em>] with a mean baseline hemoglobin concentration greater than 10 g/dL but less than 12 g/dL and reporting the percentage of
                     patients transfused, the difference between subjects treated with epoetin and control subjects was statistically significant
                     in one study <em>(</em><a id="xref-ref-53-10" class="xref-bibr" href="#ref-53"><em>53</em></a><em>).</em> Three trials <em>(</em><a id="xref-ref-45-11" class="xref-bibr" href="#ref-45"><em>45</em></a><em>,</em><a id="xref-ref-51-7" class="xref-bibr" href="#ref-51"><em>51</em></a><em>,</em><a id="xref-ref-53-11" class="xref-bibr" href="#ref-53"><em>53</em></a><em>)</em> also reported fewer RBC units transfused per patient among epoetin-treated patients, but the difference was statistically
                     significant only in one trial <em>(</em><a id="xref-ref-45-12" class="xref-bibr" href="#ref-45"><em>45</em></a><em>).</em></p>
                  
                  <p id="p-42">Of three reporting studies (n = 222; <em>(</em><a id="xref-ref-55-16" class="xref-bibr" href="#ref-55"><em>55</em></a><em>,</em><a id="xref-ref-60-11" class="xref-bibr" href="#ref-60"><em>60</em></a><em>,</em><a id="xref-ref-61-14" class="xref-bibr" href="#ref-61"><em>61</em></a><em>)</em>] with a mean baseline hemoglobin concentration of 12 g/dL or higher, the difference in the percentage of patients transfused
                     was statistically significant in one trial <em>(</em><a id="xref-ref-55-17" class="xref-bibr" href="#ref-55"><em>55</em></a><em>).</em> Fewer RBC units were transfused per patient in the two reporting studies <em>(</em><a id="xref-ref-55-18" class="xref-bibr" href="#ref-55"><em>55</em></a><em>,</em><a id="xref-ref-61-15" class="xref-bibr" href="#ref-61"><em>61</em></a><em>),</em> and the difference was statistically significant in one study <em>(</em><a id="xref-ref-55-19" class="xref-bibr" href="#ref-55"><em>55</em></a><em>).</em></p>
                  
                  <p id="p-43">As summarized in Table 2<a id="xref-table-wrap-2-3 class='xref-arrow-link'"><span>⇔</span></a>, the reported difference between epoetin and control arms in the proportion of patients transfused was similar across the
                     three groups of trials on adults: 9%–45% for those with a mean baseline hemoglobin concentration of 10 g/dL or less, 7%–47%
                     for those with a mean baseline hemoglobin concentration more than 10 g/dL but less than 12 g/dL, and 7%–39% for those with
                     a mean baseline hemoglobin concentration of 12 g/dL or higher. For RBC units per patient per 4 weeks, the differences for
                     the three groups of studies were 0–0.7, 0.1–1.3, and 0.3–0.6, respectively. Thus, the available data do not show an improvement
                     in the transfusion-sparing effects of epoetin by initiating treatment when anemia is less severe. The range of reduction in
                     the percentage of patients transfused and the number of RBC units transfused per patient was similar whether epoetin treatment
                     was initiated when the mean hemoglobin concentration was greater than 10 g/dL or was 10 g/dL or less.
                  </p>
                  
                  
                  
                  <h4>Effects of baseline hemoglobin on odds of transfusion.</h4>
                  
                  <p id="p-44"> We explored whether the effect of epoetin on the odds of transfusion depended on the groups' mean baseline hemoglobin concentration.
                     However, the association between baseline hemoglobin and odds of transfusion could be confounded by differences in study quality.
                     We could not restrict the analysis to higher quality studies because all higher quality studies that used the subcutaneous
                     route enrolled groups with a mean baseline hemoglobin concentration of 10 g/dL or less. Therefore, the evidence does not allow
                     us to test for an effect of baseline hemoglobin concentration on the odds of transfusion or to determine by meta-analysis
                     whether there is greater benefit from initiating epoetin treatment at higher hemoglobin concentrations.
                  </p>
                  
                  
                  
                  <h4>Quality-of-life outcomes.</h4>
                  
                  <p id="p-45"> The only studies <em>(</em><a id="xref-ref-41-11" class="xref-bibr" href="#ref-41"><em>41</em></a><em>,</em><a id="xref-ref-44-18" class="xref-bibr" href="#ref-44"><em>44</em></a><em>)</em> that reported a statistically significant improvement in quality-of-life outcomes attributable to epoetin treatment enrolled
                     patient groups with mean baseline hemoglobin concentrations of 10 g/dL or less (Tables 2 and 4<a id="xref-table-wrap-2-4 class='xref-arrow-link'"><span>⇔</span></a><a id="xref-table-wrap-4-5 class='xref-arrow-link'"><span>⇔</span></a>). No studies that enrolled groups with mean concentrations of more than 10 g/dL but less than 12 g/dL reported quality-of-life
                     outcomes. Of four studies <em>(</em><a id="xref-ref-54-6" class="xref-bibr" href="#ref-54"><em>54</em></a><em>,</em><a id="xref-ref-55-20" class="xref-bibr" href="#ref-55"><em>55</em></a><em>,</em><a id="xref-ref-60-12" class="xref-bibr" href="#ref-60"><em>60</em></a><em>,</em><a id="xref-ref-61-16" class="xref-bibr" href="#ref-61"><em>61</em></a><em>)</em> that enrolled groups with mean baseline hemoglobin concentrations of 12 g/dL or more and reported quality-of-life outcomes,
                     none reported a statistically significant improvement in quality of life.
                  </p>
                  
                  
                  
               </div>
               <div class="section" id="sec-20">
                  <div class="section-nav"><a href="#sec-8" title="Results" class="prev-section-link"><span>Previous Section</span></a><a href="#fn-group-1" title="Footnotes" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>D<span class="sc">iscussion</span></h2>
                  
                  <p id="p-46">The primary objectives of this review were 1) to quantify the effects of epoetin on transfusions and quality of life and 2)
                     to determine whether outcomes are superior when epoetin is initiated at higher hemoglobin thresholds. Meta-analysis of all
                     randomized studies in which epoetin was injected subcutaneously showed that epoetin reduced the odds of transfusion by a factor
                     of 0.38 compared with patients managed without epoetin, and the overall number needed to treat was 4.4.
                  </p>
                  
                  <p id="p-47">Evidence is insufficient to determine whether initiating epoetin earlier spares more patients from transfusion than waiting
                     until the hemoglobin concentration declines to nearly 10 g/dL. No studies examined this issue directly. The most robust evidence
                     that epoetin reduces the risk of transfusion comes from trials on groups with a mean baseline hemoglobin concentration of
                     10 g/dL or less. The quantitative decrease in transfusion use did not appear to be greater in trials where epoetin treatment
                     was initiated in groups with a mean hemoglobin concentration of greater than 10 g/dL compared with trials in which the mean
                     hemoglobin concentration was 10 g/dL or less. Among trials on adult patients with a baseline hemoglobin concentration of 10
                     g/dL or less, the range of differences between the epoetin and control arms for percentage of patients transfused was 9%–45%.
                     For a baseline hemoglobin concentration greater than 10 g/dL, the range was 7%–47%. This similarity in transfusion-sparing
                     effect cannot be explained by lower responsiveness to epoetin at higher hemoglobin levels, since the magnitude of the increase
                     in hematologic outcome was approximately the same, regardless of the mean baseline hemoglobin concentration.
                  </p>
                  
                  <p id="p-48">Evidence also was insufficient to conclude that starting epoetin treatment at hemoglobin concentrations much above 10 g/dL
                     results in better quality of life than starting treatment when the hemoglobin concentration declines to nearly 10 g/dL. The
                     most frequently cited data on quality-of-life outcomes after epoetin treatment are derived from uncontrolled community-based
                     studies <em>(</em><a id="xref-ref-26-2" class="xref-bibr" href="#ref-26"><em>26</em></a><em>–</em><a id="xref-ref-28-2" class="xref-bibr" href="#ref-28"><em>28</em></a><em>)</em> that report on a population with a mean baseline hemoglobin concentration less than 10 g/dL. However, these uncontrolled
                     studies did not meet the selection criteria for this systematic review and also lack key methodologic features recommended
                     to control for bias in quality-of-life measurements <em>(</em><a id="xref-ref-25-3" class="xref-bibr" href="#ref-25"><em>25</em></a><em>,</em><a id="xref-ref-29-3" class="xref-bibr" href="#ref-29"><em>29</em></a><em>–</em><a id="xref-ref-33-3" class="xref-bibr" href="#ref-33"><em>33</em></a><em>).</em> The strongest evidence for an effect of epoetin on quality of life is a randomized, double-blinded trial in a patient population
                     with a mean baseline hemoglobin concentration of 10 g/dL or less <em>(</em><a id="xref-ref-44-19" class="xref-bibr" href="#ref-44"><em>44</em></a><em>).</em> That study <em>(</em><a id="xref-ref-44-20" class="xref-bibr" href="#ref-44"><em>44</em></a><em>)</em> also reported statistically significant positive correlations between changes in hemoglobin concentration and changes in
                     quality-of-life scores. However, the trial did not actually compare the quality-of-life effects of initiating epoetin treatment
                     at alternative hemoglobin thresholds, and the analysis did not stratify patients by different hemoglobin levels at entry.
                     Trials that enrolled groups with mean baseline hemoglobin concentrations greater than 10 g/dL did not report statistically
                     significant effects of epoetin on quality-of-life outcomes.
                  </p>
                  
                  <p id="p-49">The cost of epoetin treatment has been estimated at $3700–$6600 per patient per chemotherapy cycle <em>(</em><a id="xref-ref-15-2" class="xref-bibr" href="#ref-15"><em>15</em></a><em>–</em><a id="xref-ref-17-2" class="xref-bibr" href="#ref-17"><em>17</em></a><em>).</em> These costs justify efforts to maximize the efficiency of epoetin use. The available evidence is insufficient to demonstrate
                     that initiating treatment when hemoglobin levels are still well above 10 g/dL either spares more patients from transfusion
                     or improves their quality of life.
                  </p>
                  
                  <p id="p-50">A limitation of our findings is the absence of data to permit direct analysis of the likelihood of transfusion as a function
                     of baseline hemoglobin concentration. We classified studies by mean (or, in a few instances, by median) baseline hemoglobin
                     concentrations, which might have obscured clinically important variance around that mean within studies in each category.
                     A particular concern is whether, in the group of studies for which the mean baseline hemoglobin concentration was 10 g/dL
                     or less, this classification might underestimate the benefit of epoetin to subgroups from those studies with a mean baseline
                     hemoglobin concentration of greater than 10 g/dL.
                  </p>
                  
                  <p id="p-51">Although it is possible that adequately powered comparative trials might demonstrate the superiority of initiating epoetin
                     at hemoglobin concentrations substantially greater than 10 g/dL, the extant evidence suggests two reasons not to assume that
                     earlier intervention must necessarily be better.
                  </p>
                  
                  <p id="p-52">First, in epoetin-treated groups with mean baseline hemoglobin concentrations of 10 g/dL or less, patients with values well
                     below the mean may account for a substantial proportion of transfusions. Only six trials with adult patients reported the
                     standard deviation for the mean baseline hemoglobin concentration [data not shown here; <em>see</em> comprehensive evidence report <em>(</em><a id="xref-ref-18-8" class="xref-bibr" href="#ref-18"><em>18</em></a><em>)</em>], and the mean baseline hemoglobin concentration was 10 g/dL or less in four of these trials <em>(</em><a id="xref-ref-41-12" class="xref-bibr" href="#ref-41"><em>41</em></a><em>–</em><a id="xref-ref-44-21" class="xref-bibr" href="#ref-44"><em>44</em></a><em>).</em> In two <em>(</em><a id="xref-ref-41-13" class="xref-bibr" href="#ref-41"><em>41</em></a><em>,</em><a id="xref-ref-42-10" class="xref-bibr" href="#ref-42"><em>42</em></a><em>)</em> of the four studies, patients with hemoglobin at entry greater than or equal to 1 standard deviation (SD) below the mean
                     were already near the transfusion trigger. For example, Henry et al. <em>(</em><a id="xref-ref-41-14" class="xref-bibr" href="#ref-41"><em>41</em></a><em>)</em> reported that patients in their trial were transfused at a mean hemoglobin concentration of 8.2 g/dL, while 1 SD below the
                     mean baseline hemoglobin concentration was 8.5 g/dL. Further details of this analysis are included in the complete evidence
                     report <em>(</em><a id="xref-ref-18-9" class="xref-bibr" href="#ref-18"><em>18</em></a><em>).</em></p>
                  
                  <p id="p-53">Second, patients who do not respond to epoetin may account for a substantial proportion of transfusions, irrespective of the
                     hemoglobin concentration at which epoetin treatment is initiated. Although patients with other obvious causes of anemia, for
                     which epoetin treatment would be ineffective, are excluded in these studies, not all patients are able to respond to epoetin.
                     An analysis of potential predictors of response, such as baseline serum erythropoietin concentration, failed to identify any
                     statistically significant predictors of response <em>(</em><a id="xref-ref-18-10" class="xref-bibr" href="#ref-18"><em>18</em></a><em>).</em> Nine trials <em>(</em><a id="xref-ref-40-23" class="xref-bibr" href="#ref-40"><em>40</em></a><em>–</em><a id="xref-ref-44-22" class="xref-bibr" href="#ref-44"><em>44</em></a><em>,</em><a id="xref-ref-47-5" class="xref-bibr" href="#ref-47"><em>47</em></a><em>,</em><a id="xref-ref-49-11" class="xref-bibr" href="#ref-49"><em>49</em></a><em>,</em><a id="xref-ref-52-8" class="xref-bibr" href="#ref-52"><em>52</em></a><em>,</em><a id="xref-ref-55-21" class="xref-bibr" href="#ref-55"><em>55</em></a><em>)</em> reported data that permit comparison of the percentage of nonresponders with the percentage of transfused patients in the
                     epoetin arms [data not shown here; <em>see</em> comprehensive evidence report <em>(</em><a id="xref-ref-18-11" class="xref-bibr" href="#ref-18"><em>18</em></a><em>)</em>]. Only two <em>(</em><a id="xref-ref-41-15" class="xref-bibr" href="#ref-41"><em>41</em></a><em>,</em><a id="xref-ref-42-11" class="xref-bibr" href="#ref-42"><em>42</em></a><em>)</em> of the nine trials reported that the percentage of epoetin-treated patients transfused was greater than the percentage of
                     patients failing to achieve a hematologic response, and the differences were only 1.5% and 2%, respectively. Seven <em>(</em><a id="xref-ref-40-24" class="xref-bibr" href="#ref-40"><em>40</em></a><em>,</em><a id="xref-ref-43-12" class="xref-bibr" href="#ref-43"><em>43</em></a><em>,</em><a id="xref-ref-44-23" class="xref-bibr" href="#ref-44"><em>44</em></a><em>,</em><a id="xref-ref-47-6" class="xref-bibr" href="#ref-47"><em>47</em></a><em>,</em><a id="xref-ref-49-12" class="xref-bibr" href="#ref-49"><em>49</em></a><em>,</em><a id="xref-ref-52-9" class="xref-bibr" href="#ref-52"><em>52</em></a><em>,</em><a id="xref-ref-55-22" class="xref-bibr" href="#ref-55"><em>55</em></a><em>)</em> of the nine trials reported that the percentage of nonresponding patients was greater than the percentage of patients transfused
                     in the epoetin-treated arm; the range of differences was 2.4%–39.6%.
                  </p>
                  
                  <p id="p-54">On the basis of these considerations, it appears that patients who have baseline hemoglobin concentrations well below 10 g/dL
                     and those who do not respond to epoetin could account for nearly all epoetin-treated patients who are transfused. If true,
                     this interpretation implies that the greatest yield for reducing the number of patients transfused would be obtained by preventing
                     the hemoglobin concentration from falling much below 10 g/dL rather than from setting a hemoglobin threshold well above 10
                     g/dL for initiating epoetin treatment.
                  </p>
                  
                  <p id="p-55">The evidence from this systematic review and meta-analysis also has implications for the design of any future randomized trials
                     that might directly compare different hemoglobin thresholds for initiating epoetin therapy. The meta-analysis found a smaller
                     magnitude of risk reduction for higher quality studies selected for sensitivity analysis, which were double-blinded, than
                     for lower quality, unblinded studies. Thus, the higher quality studies predict that one patient would avoid transfusion for
                     every five to six patients treated with epoetin, whereas the lower quality studies predict one for every two to three treated.
                     Note that a previous meta-analysis <em>(</em><a id="xref-ref-64-1" class="xref-bibr" href="#ref-64"><em>64</em></a><em>)</em> on fewer studies (eight studies; n = 813 randomly assigned patients) reported that the magnitude of reduction in transfusion
                     requirements was similar across strata defined by methodologic quality. However, fewer unblinded studies were available for
                     the earlier meta-analysis.
                  </p>
                  
                  <p id="p-56">There is some evidence that, in unblinded studies, physicians may be more aggressive in transfusing patients in the control
                     arm, thus overestimating the observed effect of epoetin. The authors of one study <em>(</em><a id="xref-ref-55-23" class="xref-bibr" href="#ref-55"><em>55</em></a><em>)</em> noted a tendency for physicians in this unblinded trial to undertransfuse patients in the arm with the higher epoetin dose.
                     Patients in the high-dose arm were transfused at a mean hemoglobin level of 8.0 g/dL, while those in the control and low-dose
                     arms were transfused at mean hemoglobin levels of 8.5 and 8.6 g/dL, respectively. The authors hypothesized that this situation
                     may have inflated the magnitude of effect. This also implies that a patient-level meta-analysis on existing studies to assess
                     whether earlier epoetin intervention results in superior outcomes would be of questionable value, even if feasible. Almost
                     all patients with baseline hemoglobin concentrations greater than 10 g/dL were studied in unblinded trials, which are subject
                     to bias in transfusion orders and thus in measuring the effect of epoetin on transfusions.
                  </p>
                  
                  <p id="p-57">The systematic review identified opportunities to improve the standard of study design and reporting for future trials of
                     epoetin and other supportive therapies for oncology patients. We had substantial concern about the impact of subjective judgments
                     regarding the need to transfuse on measurement of treatment outcomes in the available trials. Other deficiencies common to
                     this literature included inadequate statistical power, failure to report on concealment of allocation, failure to consistently
                     report on a common set of clinically relevant outcomes, failure to consistently test and report on statistical significance,
                     failure to account for patients lost to follow-up or excluded from the analysis, failure to use intent-to-treat analyses,
                     and failure to use procedures for minimizing bias in measuring quality of life. In addition, many of these studies suffered
                     from incompleteness of reporting. Future trials should conform to the recommendations of the CONSORT <em>(</em><a id="xref-ref-24-2" class="xref-bibr" href="#ref-24"><em>24</em></a><em>).</em> Future trials also should specify a transfusion trigger and should report the mean hemoglobin levels at which transfusion
                     actually occurred in each arm.
                  </p>
                  
                  <p id="p-58">Finally, future trials should prospectively stratify patients by characteristics of interest and report outcomes separately
                     for these stratified subgroups. Such characteristics include type of malignancy, prior treatments, therapeutic regimen, and
                     predictors of response. These considerations will produce a more robust body of cumulative evidence by improving the ability
                     to compare results among trials and by increasing the potential for combined analyses.
                  </p>
                  
                  <p id="p-59">In conclusion, epoetin reduces the odds of transfusion for cancer patients undergoing therapy, but double-blind studies with
                     less than 10% exclusions reported smaller effects. The number of patients needed to treat to prevent one transfusion is 4.4
                     for all studies, 5.2 for higher quality studies, and 2.6 for lower quality studies. Only studies with a mean baseline hemoglobin
                     concentration of 10 g/dL or less reported statistically significant effects on quality of life; data were insufficient for
                     a meta-analysis. The available evidence is inadequate to determine whether outcomes are superior if epoetin treatment is initiated
                     when the hemoglobin concentration is substantially higher than 10 g/dL, compared with starting the treatment when the hemoglobin
                     concentration declines to nearly 10 g/dL. Randomized, controlled trials, double-blinded and adequately powered, are needed.
                     Inferences from indirect comparison of the results of the available trials cannot resolve this question.
                  </p>
                  
               </div>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Jerome+Seidenfeld&amp;sortspec=date&amp;submit=Submit">Jerome Seidenfeld</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Margaret+Piper&amp;sortspec=date&amp;submit=Submit">Margaret Piper</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-3" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Carole+Flamm&amp;sortspec=date&amp;submit=Submit">Carole Flamm</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-4" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Victor+Hasselblad&amp;sortspec=date&amp;submit=Submit">Victor Hasselblad</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-5" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=James+O.+Armitage&amp;sortspec=date&amp;submit=Submit">James O. Armitage</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-6" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Charles+L.+Bennett&amp;sortspec=date&amp;submit=Submit">Charles L. Bennett</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-7" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Michael+S.+Gordon&amp;sortspec=date&amp;submit=Submit">Michael S. Gordon</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-8" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Allan+E.+Lichtin&amp;sortspec=date&amp;submit=Submit">Allan E. Lichtin</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-9" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=James+L.+Wade+III&amp;sortspec=date&amp;submit=Submit">James L. Wade III</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-10" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Steven+Woolf&amp;sortspec=date&amp;submit=Submit">Steven Woolf</a></span> and 
                     </li>
                     <li class="last" id="contrib-11"><span class="name"><a class="name-search"
                              href="/search?author1=Naomi+Aronson&amp;sortspec=date&amp;submit=Submit">Naomi Aronson</a></span></li>
                  </ol>
                  <ol class="affiliation-list">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address><em>Affiliations of authors:</em> J. Seidenfeld, M. Piper, C. Flamm, N. Aronson, Technology Evaluation Center, Blue Cross and Blue Shield Association, Chicago,
                           IL; V. Hasselblad, Duke University, Durham, NC; J. O. Armitage, University of Nebraska Medical Center, Omaha; C. L. Bennett,
                           Department of Veterans Affairs Chicago Healthcare System/Lakeside Division and Northwestern University, Chicago, IL; M. S.
                           Gordon, University of Arizona College of Medicine, Phoenix Campus; A. E. Lichtin, Cleveland Clinic Foundation, OH; J. L. Wade
                           III, Cancer Care Specialists, Decatur, IL; S. Woolf, Medical College of Virginia, Richmond.
                        </address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="fn" id="corresp-1"><em>Correspondence to:</em> Jerome Seidenfeld, Ph.D., Technology Evaluation Center, Blue Cross and Blue Shield Association, 225 North Michigan Ave.,
                        Chicago, IL 60601–7680 (e-mail: <span class="em-link"><span class="em-addr">jerome.seidenfeld{at}bcbsa.com</span></span>).
                     </li>
                  </ol>
                  <ul class="history-list">
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="received"
                         hwp:start="2000-12-01"><span class="received-label">Received </span>December 1, 2000.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd"
                         hwp:start="2001-06-07"><span class="rev-recd-label">Revision received </span>June 7, 2001.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted"
                         hwp:start="2001-06-12"><span class="accepted-label">Accepted </span>June 12, 2001.
                     </li>
                  </ul>
               </div>
               <div class="section fn-group" id="fn-group-1">
                  <div class="section-nav"><a href="#sec-20" title="Discussion" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Footnotes</h2>
                  <ul>
                     <li class="fn" id="fn-1">
                        
                        
                        <p id="p-66"><a class="rev-xref" href="#xref-fn-1-1">↵</a><span class="fn-label">1</span> The study published by Littlewood et al. <em>(</em><a id="xref-ref-44-24" class="xref-bibr" href="#ref-44"><em>44</em></a><em>)</em> was reviewed in detail; there were no substantial changes in results that affected the analyses or conclusions in this review,
                           which were based on an earlier version.
                        </p>
                        
                     </li>
                     <li class="fn" id="fn-2">
                        
                        <p id="p-67"><em>Editor's note:</em> C. L. Bennett has received grants in the past from Amgen (Thousand Oaks, CA) and Ortho-Biotech (Raritan, NJ) and has done
                           consulting work for Amgen. M. S. Gordon has served on a scientific advisory board for Amgen regarding anemia and occasionally
                           speaks on the topic. J. L. Wade III participated as an investigator in an open-cohort study on Procrit for the treatment of
                           anemia secondary to chemotherapy; the study was sponsored by Ortho-Biotech.
                        </p>
                        
                     </li>
                     <li class="fn" id="fn-3">
                        
                        <p id="p-68">This work was developed under contract with the Agency for Healthcare Research and Quality (AHRQ) contract number 290–97–0015.
                           The Blue Cross and Blue Shield Association Technology Evaluation Center is an Evidence-Based Practice Center of the AHRQ.
                        </p>
                        
                     </li>
                     <li class="fn" id="fn-4">
                        
                        <p id="p-69">The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement
                           in this article should be construed as an official position of the AHRQ or of the U.S. Department of Health and Human Services.
                        </p>
                        
                     </li>
                  </ul>
               </div>
               <ul>
                  <li class="fn" id="copyright-statement-1">© Oxford University Press</li>
               </ul>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#fn-group-1" title="Footnotes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2>R<span class="sc">eferences</span></h2>
                  <ol class="cit-list">
                     <li><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference 1 in text"
                           id="ref-1">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.1"
                             data-doi="10.2165/00003495-198938060-00004">
                           <div class="cit-metadata"><cite>Faulds D, Sorkin EM. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties
                                 and therapeutic potential in anaemia and the stimulation of erythropoiesis. <span class="cit-source">Drugs</span> <span class="cit-pub-date">1989</span>;<span class="cit-vol">38</span>:<span class="cit-fpage">863</span>–99.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.2165/00003495-198938060-00004&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=2693045&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1989CF44000003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-93.16.1204.2"
                             data-doi="10.1056/NEJM199703273361307">
                           <div class="cit-metadata"><cite>Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. <span class="cit-source">N Engl J Med</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">336</span>:<span class="cit-fpage">933</span>–8.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM199703273361307&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9070475&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1997WP83200007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference 3 in text"
                           id="ref-3">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.3">
                           <div class="cit-metadata"><cite>Spivak JL. Recombinant human erythropoietin and the anemia of cancer. <span class="cit-source">Blood</span> <span class="cit-pub-date">1994</span>;<span class="cit-vol">84</span>:<span class="cit-fpage">997</span>–1004.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=PDF&amp;journalCode=bloodjournal&amp;resid=84/4/997"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference 4 in text"
                           id="ref-4">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.4"
                             data-doi="10.1056/NEJM198907203210305">
                           <div class="cit-metadata"><cite>Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant
                                 human erythropoietin. <span class="cit-source">N Engl J Med</span> <span class="cit-pub-date">1989</span>;<span class="cit-vol">321</span>:<span class="cit-fpage">158</span>–63.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM198907203210305&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=2747747&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1989AG03900005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference 5 in text"
                           id="ref-5">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.5">
                           <div class="cit-metadata"><cite>Muirhead N, Bargman J, Burgess E, Jindal KK, Levin A, Nolin L, et al. Evidence-based recommendations for the clinical use
                                 of recombinant human erythropoietin. <span class="cit-source">Am J Kidney Dis</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">26</span>(2 Suppl 1):<span class="cit-fpage">S1</span>–24.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7573030&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995RZ03700001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference 6 in text"
                           id="ref-6">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.6">
                           <div class="cit-metadata"><cite>Armitage JO. Management of anemia in patients with cancer. <span class="cit-source">Clin Oncol Updates</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">1</span>:<span class="cit-fpage">1</span>–12.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference 7 in text"
                           id="ref-7">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.7">
                           <div class="cit-metadata"><cite>Ludwig H, Fritz EA. Anemia in cancer patients. <span class="cit-source">Semin Oncol</span> <span class="cit-pub-date">1998</span>; <span class="cit-vol">25</span>(3 Suppl 7):<span class="cit-fpage">2</span>–6.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference 8 in text"
                           id="ref-8">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.8"
                             data-doi="10.1016/S0889-8588(05)70342-7">
                           <div class="cit-metadata"><cite>Moliterno AR, Spivak JL. Anemia of cancer. <span class="cit-source">Hematol Oncol Clin North Am</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">10</span>:<span class="cit-fpage">345</span>–63.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0889-8588(05)70342-7&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8707759&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1996UC64900004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-93.16.1204.9">
                           <div class="cit-metadata"><cite>Henry DH. Epoetin alfa and high-dose chemotherapy. <span class="cit-source">Semin Oncol</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">25</span>(3 Suppl 7):<span class="cit-fpage">54</span>–7.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference 10 in text"
                           id="ref-10">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.10">
                           <div class="cit-metadata"><cite>Markham A, Bryson HM. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in
                                 nonrenal applications. <span class="cit-source">Drugs</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">49</span>:<span class="cit-fpage">232</span>–54.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7729331&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995QD99700008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference 11 in text"
                           id="ref-11">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.11"
                             data-doi="10.1093/jnci/91.19.1616">
                           <div class="cit-metadata"><cite>Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. <span class="cit-source">J Natl Cancer Inst</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">91</span>:<span class="cit-fpage">1616</span>–34.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=91/19/1616"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference 12 in text"
                           id="ref-12">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.12">
                           <div class="cit-metadata"><cite>Aledort LM, Mohandas K. Transfusion requirements in patients with malignancy. <span class="cit-source">Semin Hematol</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">33</span>(1 Suppl 1):<span class="cit-fpage">6</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=8714609&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1996TV46300003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-93.16.1204.13"
                             data-doi="10.1046/j.1537-2995.1998.38698326341.x">
                           <div class="cit-metadata"><cite>Valeri CR, Crowley JP, Loscalzo J. The red cell transfusion trigger: has a sin of commission now become a sin of omission?
                                 <span class="cit-source">Transfusion</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">38</span>:<span class="cit-fpage">602</span>–10.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1046/j.1537-2995.1998.38698326341.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9661695&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000074561900012&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference 14 in text"
                           id="ref-14">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.14">
                           <div class="cit-metadata unstructured">Schroeder ML. Principles and practice of transfusion medicine. Chap. 27. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer
                              JP, Rodgers GM, editors. Wintrobe's clinical hematology. 10<sup>th</sup> ed. Baltimore (MD): Williams &amp; Wilkins; 1999.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference 15 in text"
                           id="ref-15">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.15"
                             data-doi="10.1002/(SICI)1097-0142(19981215)83:12&lt;2588::AID-CNCR26&gt;3.0.CO;2-M">
                           <div class="cit-metadata"><cite>Ortega A, Dranitsaris G, Puodziunas AL. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost–benefit
                                 analysis. <span class="cit-source">Cancer</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">83</span>:<span class="cit-fpage">2588</span>–96.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/(SICI)1097-0142(19981215)83:12%3C2588::AID-CNCR26%3E3.0.CO;2-M&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9874467&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000077731700026&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-93.16.1204.16">
                           <div class="cit-metadata"><cite>Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of human erythropoietin in the prevention of chemotherapy-induced anemia.
                                 <span class="cit-source">Br J Cancer</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">78</span>:<span class="cit-fpage">781</span>–7.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=9743301&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000075803500015&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference 17 in text"
                           id="ref-17">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.17"
                             data-doi="10.2165/00019053-199916050-00004">
                           <div class="cit-metadata"><cite>Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB. Cost effectiveness, quality-adjusted life-years and supportive
                                 care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. <span class="cit-source">Pharmacoeconomics</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">16</span>(5 Pt 1):<span class="cit-fpage">459</span>–72.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.2165/00019053-199916050-00004&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10662393&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000083543000004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference 18 in text"
                           id="ref-18">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.18">
                           <div class="cit-metadata unstructured">Aronson N, Seidenfeld J, Piper MA, Flamm C, Hasselblad V. Use of erythropoietin in oncology. Evidence report/technology assessment
                              No. 30. Prepared by the Blue Cross and Blue Shield Association Evidence-based Practice Center under Contract No. 290–97–0015.
                              AHRQ Publ No. 01-E009. Rockville (MD): Agency for Healthcare Research and Quality; June 2001.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference 19 in text"
                           id="ref-19">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.19">
                           <div class="cit-metadata unstructured">Mulrow CD, Oxman AD, editors. Cochrane collaboration handbook. Available in the Cochrane Library [database on disk and CD-ROM].
                              The Cochrane Collaboration. Issue 1. Oxford (U.K.): Update Software; 1997.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference 20 in text"
                           id="ref-20">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.20"
                             data-doi="10.1001/jama.1995.03520290060030">
                           <div class="cit-metadata"><cite>Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with
                                 estimates of treatment effects in controlled trials. <span class="cit-source">JAMA</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">273</span>:<span class="cit-fpage">408</span>–12.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/jama.1995.03520290060030&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7823387&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995QD20300026&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-93.16.1204.21"
                             data-doi="10.1001/jama.282.11.1054">
                           <div class="cit-metadata"><cite>Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. <span class="cit-source">JAMA</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">282</span>:<span class="cit-fpage">1054</span>–60.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/jama.282.11.1054&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10493204&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000082512300029&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference 22 in text"
                           id="ref-22">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.22"
                             data-doi="10.1016/S0140-6736(98)01085-X">
                           <div class="cit-metadata"><cite>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised controlled trials affect
                                 estimates of intervention efficacy reported in meta-analyses? <span class="cit-source">Lancet</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">352</span>:<span class="cit-fpage">609</span>–13</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(98)01085-X&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9746022&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000075567400010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference 23 in text"
                           id="ref-23">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.23"
                             data-doi="10.1001/jama.282.11.1083">
                           <div class="cit-metadata"><cite>Berlin JA, Rennie D. Measuring the quality of trials: the quality of the quality scales. <span class="cit-source">JAMA</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">282</span>:<span class="cit-fpage">1083</span>–5.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/jama.282.11.1083&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10493209&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000082512300034&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference 24 in text"
                           id="ref-24">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.24"
                             data-doi="10.1001/jama.1996.03540080059030">
                           <div class="cit-metadata"><cite>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized trials. The
                                 CONSORT statement. <span class="cit-source">JAMA</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">276</span>:<span class="cit-fpage">637</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/jama.1996.03540080059030&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8773637&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1996VC85300031&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference 25 in text"
                           id="ref-25">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.25"
                             data-doi="10.1046/j.1524-4733.1999.02210.x">
                           <div class="cit-metadata"><cite>Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion.
                                 <span class="cit-source">Value Health</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">2</span>:<span class="cit-fpage">113</span>–27.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1046/j.1524-4733.1999.02210.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16674343&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-26-1" title="View reference 26 in text"
                           id="ref-26">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.26">
                           <div class="cit-metadata"><cite>Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical
                                 outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study
                                 Group. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">15</span>:<span class="cit-fpage">1218</span>–34.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=15/3/1218"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-93.16.1204.27">
                           <div class="cit-metadata"><cite>Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is
                                 independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">16</span>:<span class="cit-fpage">3412</span>–25.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=16/10/3412"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-28-1" title="View reference 28 in text"
                           id="ref-28">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.28">
                           <div class="cit-metadata"><cite>Gabrilove JL, Einhorn LH, Livingston RB, Winer E, Cleeland CS. Once-weekly dosing of epoetin alfa is similar to three-times-weekly
                                 dosing in increasing hemoglobin and quality of life [abstract]. <span class="cit-source">Proc ASCO</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">18</span>:<span class="cit-fpage">574a</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-29-1" title="View reference 29 in text"
                           id="ref-29">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.29">
                           <div class="cit-metadata unstructured">Nayfield SG, Hailey BJ. Quality of life assessment in cancer clinical trials. Report of the Workshop on Quality of Life Research
                              in Cancer Clinical Trials. Bethesda (MD): National Cancer Institute; 1990.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-93.16.1204.30"
                             data-doi="10.1002/1097-0142(19910201)67:3+&lt;844::AID-CNCR2820671416&gt;3.0.CO;2-B">
                           <div class="cit-metadata"><cite>Aaronson NK. Methodologic issues in assessing the quality of life of cancer patients. <span class="cit-source">Cancer</span> <span class="cit-pub-date">1991</span>;<span class="cit-vol">67</span>(3 Suppl):<span class="cit-fpage">844</span>–50.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(19910201)67:3+%3C844::AID-CNCR2820671416%3E3.0.CO;2-B&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=1986856&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1991FL82200015&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference 31 in text"
                           id="ref-31">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.31">
                           <div class="cit-metadata"><cite>Osoba D. Lessons learned from measuring health-related quality of life in oncology. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1994</span>;<span class="cit-vol">12</span>:<span class="cit-fpage">608</span>–16.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=12/3/608"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference 32 in text"
                           id="ref-32">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.32">
                           <div class="cit-metadata"><cite>Beitz J, Gnecco C, Justice R. Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration
                                 perspective. <span class="cit-source">J Natl Cancer Inst Monogr</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">20</span>:<span class="cit-fpage">7</span>–9.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-33-1" title="View reference 33 in text"
                           id="ref-33">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.33">
                           <div class="cit-metadata"><cite>Beitz J. Quality-of-life end points in oncology drug trials. <span class="cit-source">Oncology (Huntingt)</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">13</span>:<span class="cit-fpage">1439</span>–42; discussion, 1442.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10549568&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-34-1" title="View reference 34 in text"
                           id="ref-34">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.34">
                           <div class="cit-metadata unstructured">Hedges LV, Olkin I, editors. Statistical methods for meta-analysis. Orlando (FL): Academic Press; 1985.</div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-35-1" title="View reference 35 in text"
                           id="ref-35">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.35">
                           <div class="cit-metadata unstructured">Eddy DM, Hasselblad V. FAST*PRO Software for meta-analysis by the confidence profile method. Orlando (FL): Academic Press;
                              1992.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-36-1" title="View reference 36 in text"
                           id="ref-36">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.36"
                             data-doi="10.1016/0197-2456(86)90046-2">
                           <div class="cit-metadata"><cite>DerSimonian R, Laird N. Meta-analysis in clinical trials. <span class="cit-source">Control Clin Trials</span> <span class="cit-pub-date">1986</span>;<span class="cit-vol">7</span>:<span class="cit-fpage">177</span>–88.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0197-2456(86)90046-2&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=3802833&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1986F013900001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-37-1" title="View reference 37 in text"
                           id="ref-37">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.37">
                           <div class="cit-metadata unstructured">Egret statistical software. Seattle (WA): Statistics in Epidemiology Research Corporation; 1996.</div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-38-1" title="View reference 38 in text"
                           id="ref-38">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.38"
                             data-doi="10.1177/0272989X9801800110">
                           <div class="cit-metadata"><cite>Hasselblad V. Meta-analysis of multi-treatment studies. <span class="cit-source">Med Decis Making</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">18</span>:<span class="cit-fpage">37</span>–43.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=spmdm&amp;resid=18/1/37"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-39-1" title="View reference 39 in text"
                           id="ref-39">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.39"
                             data-doi="10.1056/NEJM198806303182605">
                           <div class="cit-metadata"><cite>Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. <span class="cit-source">N Engl J Med</span> <span class="cit-pub-date">1988</span>;<span class="cit-vol">318</span>:<span class="cit-fpage">1728</span>–33.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM198806303182605&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=3374545&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1988N994800005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-40-1" title="View reference 40 in text"
                           id="ref-40">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.40"
                             data-doi="10.1093/jnci/85.10.801">
                           <div class="cit-metadata"><cite>Case DC Jr, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, et al. Recombinant human erythropoietin therapy for
                                 anemic cancer patients on combination chemotherapy. <span class="cit-source">J Natl Cancer Inst</span> <span class="cit-pub-date">1993</span>;<span class="cit-vol">85</span>:<span class="cit-fpage">801</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=85/10/801"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-41-1" title="View reference 41 in text"
                           id="ref-41">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.41">
                           <div class="cit-metadata"><cite>Henry DH, Brooks BJ Jr, Case DC Jr, Fishkin E, Jacobson R, Keller AM, et al. Recombinant human erythropoietin therapy for
                                 anemic cancer patients receiving cisplatin chemotherapy. <span class="cit-source">Cancer J Sci Am</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">1</span>:<span class="cit-fpage">252</span>–60.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=9166485&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-42-1" title="View reference 42 in text"
                           id="ref-42">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.42">
                           <div class="cit-metadata"><cite>Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated
                                 anemia: a randomized, double-blind trial with placebo. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1994</span>;<span class="cit-vol">12</span>:<span class="cit-fpage">1058</span>–62.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=12/5/1058"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-43-1" title="View reference 43 in text"
                           id="ref-43">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.43"
                             data-doi="10.1006/gyno.1997.4675">
                           <div class="cit-metadata"><cite>Kurz C, Marth C, Windbichler G, Lahousen M, Medl M, Vavra N, et al. Erythropoietin treatment under polychemotherapy in patients
                                 with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. <span class="cit-source">Gynecol Oncol</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">65</span>:<span class="cit-fpage">461</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1006/gyno.1997.4675&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9190976&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1997XE19500018&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-44-1" title="View reference 44 in text"
                           id="ref-44">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.44">
                           <div class="cit-metadata"><cite>Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality
                                 of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
                                 <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">19</span>:<span class="cit-fpage">2865</span>–74.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=19/11/2865"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-45-1" title="View reference 45 in text"
                           id="ref-45">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.45"
                             data-doi="10.1046/j.1537-2995.1996.36296181929.x">
                           <div class="cit-metadata"><cite>Wurnig C, Windhager R, Schwameis E, Kotz R, Zoubek A, Stockenhuber F, et al. Prevention of chemotherapy-induced anemia by
                                 the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). <span class="cit-source">Transfusion</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">36</span>:<span class="cit-fpage">155</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1046/j.1537-2995.1996.36296181929.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8614967&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1996TX29700013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-46-1" title="View reference 46 in text"
                           id="ref-46">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.46"
                             data-doi="10.1016/S0022-3476(96)70145-2">
                           <div class="cit-metadata"><cite>Porter JC, Leahey A, Polise K, Bunin G, Manno CS. Recombinant human erythropoietin reduces the need for erythrocyte and platelet
                                 transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. <span class="cit-source">J Pediatr</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">129</span>:<span class="cit-fpage">656</span>–60.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0022-3476(96)70145-2&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8917229&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1996VR95700010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-47-1" title="View reference 47 in text"
                           id="ref-47">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.47"
                             data-doi="10.1006/gyno.1993.1102">
                           <div class="cit-metadata"><cite>Markman M, Reichman B, Hakes T, Rubin S, Jones W, Lewis JL Jr, et al. The use of recombinant human erythropoietin to prevent
                                 carboplatin-induced anemia. <span class="cit-source">Gynecol Oncol</span> <span class="cit-pub-date">1993</span>;<span class="cit-vol">49</span>:<span class="cit-fpage">172</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1006/gyno.1993.1102&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8504984&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1993LG21300005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-93.16.1204.48">
                           <div class="cit-metadata"><cite>Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. <span class="cit-source">Int J Radiat Oncol Biol Phys</span> <span class="cit-pub-date">1993</span>;<span class="cit-vol">27</span>:<span class="cit-fpage">1147</span>–52.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=8262840&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1993ML94700021&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-49-1" title="View reference 49 in text"
                           id="ref-49">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.49"
                             data-doi="10.1002/(SICI)1096-911X(199802)30:2&lt;110::AID-MPO8&gt;3.0.CO;2-L">
                           <div class="cit-metadata"><cite>Leon P, Jimenez M, Barona P, Sierrasesumaga L. Recombinant human erythropoietin for the treatment of anemia in children with
                                 solid malignant tumors. <span class="cit-source">Med Pediatr Oncol</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">30</span>:<span class="cit-fpage">110</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/(SICI)1096-911X(199802)30:2%3C110::AID-MPO8%3E3.0.CO;2-L&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9403020&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1998YJ55600008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-50-1" title="View reference 50 in text"
                           id="ref-50">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.50">
                           <div class="cit-metadata"><cite>Dusenbery KE, McGuire WA, Holt PJ, Carson LF, Fowler JM, Twiggs LB, et al. Erythropoietin increases hemoglobin during radiation
                                 therapy for cervical cancer. <span class="cit-source">Int J Radiat Oncol Biol Phys</span> <span class="cit-pub-date">1994</span>;<span class="cit-vol">29</span>:<span class="cit-fpage">1079</span>–84.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=8083076&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1994PE33800018&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-51-1" title="View reference 51 in text"
                           id="ref-51">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.51">
                           <div class="cit-metadata"><cite>Quirt I, Coutere F, Pichette R, Olweny C, White D, King M, et al. The role of recombinant human erythropoietin (EPO) in reducing
                                 red blood cell transfusions and maintaining quality of life (QOL) in patients with lymphoma and solid tumors receiving cytotoxic
                                 chemotherapy: results of a randomized, double-blind, placebo-controlled clinical trial [abstract]. <span class="cit-source">Blood</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">88</span>(10 Suppl 1):<span class="cit-fpage">347a</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-52-1" title="View reference 52 in text"
                           id="ref-52">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.52"
                             data-doi="10.1023/A:1008296622469">
                           <div class="cit-metadata"><cite>Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, et al. Recombinant human erythropoietin in the treatment of
                                 chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled
                                 study. <span class="cit-source">Ann Oncol</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">9</span>:<span class="cit-fpage">255</span>–60.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=9/3/255"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-53-1" title="View reference 53 in text"
                           id="ref-53">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.53"
                             data-doi="10.1007/BF02821936">
                           <div class="cit-metadata"><cite>ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, et al. Controlled multicentre study of the
                                 influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian
                                 carcinoma treated with platinum-based chemotherapy. <span class="cit-source">Med Oncol</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">15</span>:<span class="cit-fpage">174</span>–82.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1007/BF02821936&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9819794&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000079462700005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-54-1" title="View reference 54 in text"
                           id="ref-54">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.54">
                           <div class="cit-metadata"><cite>Sweeney PJ, Nicolae D, Ignacio L, Chen L, Roach M 3<sup>rd</sup>, Wara W, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final
                                 report of a randomized, open-labelled, phase II trial. <span class="cit-source">Br J Cancer</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">77</span>:<span class="cit-fpage">1996</span>–2002.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=9667681&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000080207600044&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-55-1" title="View reference 55 in text"
                           id="ref-55">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.55"
                             data-doi="10.1038/sj.bjc.6690369">
                           <div class="cit-metadata"><cite>Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, et al. Epoetin alpha prevents anaemia and reduces transfusion
                                 requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. <span class="cit-source">Br J Cancer</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">80</span>:<span class="cit-fpage">396</span>–402.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/sj.bjc.6690369&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10408844&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000080028900013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-93.16.1204.56">
                           <div class="cit-metadata"><cite>Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F. Long-term therapy with recombinant human erythropoietin (rHu-EPO)
                                 in progressing multiple myeloma. <span class="cit-source">Ann Hematol</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">70</span>:<span class="cit-fpage">313</span>–8.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7632811&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995RM62700005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-57-1" title="View reference 57 in text"
                           id="ref-57">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.57">
                           <div class="cit-metadata"><cite>Varan A, Buyukpamukcu M, Kutluk T, Akyuz C. Recombinant human erythropoietin treatment for chemotherapy-related anemia in
                                 children. <span class="cit-source">Pediatrics</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">103</span>:<span class="cit-fpage">E16</span>–4.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-93.16.1204.58"
                             data-doi="10.1016/S0167-8140(98)00115-7">
                           <div class="cit-metadata"><cite>Henke M, Guttenberger R, Barke A, Pajonk F, Potter R, Frommhold H. Erythropoietin for patients undergoing radiotherapy: a
                                 pilot study. <span class="cit-source">Radiother Oncol</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">50</span>:<span class="cit-fpage">185</span>–90.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0167-8140(98)00115-7&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10368042&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000079523900008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-93.16.1204.59"
                             data-doi="10.1016/0959-8049(93)90662-Y">
                           <div class="cit-metadata"><cite>Gamucci T, Thorel MF, Frasca AM, Giannarell D, Calabresi F. Erythropoietin for the prevention of anaemia in neoplastic patients
                                 treated with cisplatin. <span class="cit-source">Eur J Cancer</span> <span class="cit-pub-date">1993</span>;<span class="cit-vol">29</span>A Suppl 2:<span class="cit-fpage">S13</span>–4.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0959-8049(93)90662-Y&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-60-1" title="View reference 60 in text"
                           id="ref-60">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.60">
                           <div class="cit-metadata"><cite>Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, et al. Randomized phase III trial evaluating the
                                 role of erythropoietin in the prevention of chemotherapy-induced anemia. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">15</span>:<span class="cit-fpage">2715</span>–21.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=15/7/2715"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-61-1" title="View reference 61 in text"
                           id="ref-61">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.61">
                           <div class="cit-metadata"><cite>Welch RS, James RD, Wilkinson PM, Belli F, Cowan RA. Recombinant human erythropoietin and platinum-based chemotherapy in advanced
                                 ovarian cancer. <span class="cit-source">Cancer J Sci Am</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">1</span>:<span class="cit-fpage">261</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=9166486&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-62-1" title="View reference 62 in text"
                           id="ref-62">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.62">
                           <div class="cit-metadata"><cite>Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development
                                 and validation of the general measure. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1993</span>;<span class="cit-vol">11</span>:<span class="cit-fpage">570</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=11/3/570"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-63-1" title="View reference 63 in text"
                           id="ref-63">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.63">
                           <div class="cit-metadata"><cite>Cella D. The Functional Assessment of Cancer Therapy—Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in
                                 cancer anemia and fatigue. <span class="cit-source">Semin Hematol</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">34</span>(3 Suppl 2):<span class="cit-fpage">13</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=9122741&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1997WG17400003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><a class="rev-xref-ref" href="#xref-ref-64-1" title="View reference 64 in text"
                           id="ref-64">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-93.16.1204.64">
                           <div class="cit-metadata"><cite>Quirt I, Micucci S, Moran LA, Pater J, Browman G. Erythropoietin in the management of patients with nonhematologic cancer
                                 receiving chemotherapy. Systemic Treatment Program Committee. <span class="cit-source">Cancer Prev Control</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">1</span>:<span class="cit-fpage">241</span>–8.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=9765749&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div><span id="related-urls"></span></div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/93/16/1203.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/93/16/1215.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/93/16.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="JNCI Journal of the National Cancer Institute" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">JNCI J Natl Cancer Inst</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">
                                    (2001) 
                                    </span>
                                 
                                 <span class="slug-vol">
                                    93
                                    </span><span class="slug-issue">
                                    (16):
                                    </span><span class="slug-pages">
                                    1204-1214.
                                    </span>
                                 <span class="slug-doi-wrapper">
                                    
                                    doi:
                                    
                                    <span title="10.1093/jnci/93.16.1204" class="slug-doi">10.1093/jnci/93.16.1204</span>
                                    </span>
                                 </cite>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/93/16/1204.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="/content/93/16/1204.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Classifications</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=REVIEW&amp;sortspec=date&amp;submit=Submit">Review</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="usage-stats-link icon-link"><a href="/articleusage?gca=jnci;93/16/1204" rel="nofollow">Article metrics</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jnci%3B93%2F16%2F1204&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/93/16/1204.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=93/16/1204&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/93/16/1204.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="/search?qbe=jnci%3B93%2F16%2F1204&amp;citation=Seidenfeld%20et%20al.%2093%20%2816%29:%201204&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=jnci%3B93%2F16%2F1204&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=11504766&amp;link_type=MED_NBRS"
                              class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jnci%3B93%2F16%2F1204">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=jnci%3B93%2F16%2F1204">Download citation</a></li>
                        <li><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jnci&amp;title=Epoetin%20Treatment%20of%20Anemia%20Associated%20With%20Cancer%20Therapy%3A%20a%20Systematic%20Review%20and%20Meta-analysis%20of%20Controlled%20Clinical%20Trials%3A%20&amp;publicationDate=08%2F15%2F2001&amp;author=Jerome%20Seidenfeld%2C%20Margaret%20Piper%2C%20Carole%20Flamm%2C%20Victor%20Hasselblad%2C%20James%20O.%20Armitage%2C%20Charles%20L.%20Bennett%2C%20Michael%20S.%20Gordon%2C%20Allan%20E.%20Lichtin%2C%20James%20L.%20Wade%20III%2C%20Steven%20Woolf%2C%20Naomi%20Aronson&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjnci%2F93.16.1204&amp;volumeNum=93&amp;issueNum=16&amp;startPage=1204&amp;endPage=1214&amp;orderBeanReset=true"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/93/16/1204.full?cited-by=yes&amp;legid=jnci;93/16/1204#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/cgi/crossref-forward-links/93/16/1204" rel="external-nw"
                              id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a href="/scopus-links/jnci/93/16/1204?access_num=/jnci/93/16/1204"
                              rel="external-nw"
                              id="cb-scopus-citing-articles">Citing articles via Scopus</a></li>
                        <li><a href="/external-ref?access_num=%2Fjnci%2F93%2F16%2F1204&amp;link_type=ISI_CITING&amp;accnum_type=native"
                              rel="external-nw"
                              id="cb-isi-citing-articles">Citing articles via Web of Science</a></li>
                        <li><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/93/16/1204.abstract&amp;link_type=GOOGLESCHOLAR">Citing articles via Google Scholar</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3ASeidenfeld%20author%3AJ.%22"
                              class="cb-art-gs-auth author-link">Articles by  Seidenfeld, J.</a></li>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AAronson%20author%3AN.%22"
                              class="cb-art-gs-auth author-link">Articles by  Aronson, N.</a></li>
                        <li class="cb-art-gs-rel similar-link"><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/93/16/1204.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=11504766&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Seidenfeld%20J&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Seidenfeld, J.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Piper%20M&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Piper, M.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Flamm%20C&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Flamm, C.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Hasselblad%20V&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Hasselblad, V.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Armitage%20JO&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Armitage, J. O.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Bennett%20CL&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Bennett, C. L.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Gordon%20MS&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Gordon, M. S.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Lichtin%20AE&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Lichtin, A. E.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Wade%20JL&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Wade, J. L.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Woolf%20S&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Woolf, S.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Aronson%20N&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Aronson, N.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="/content/93/16/1204.full?related-urls=yes&amp;legid=jnci;93/16/1204#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Share</span></h4>
                     <ol>
                        <li><a href="/email?gca=jnci%3B93%2F16%2F1204&amp;current-view-path=/content/93/16/1204.full">
                              Email this article</a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/93/16/1204&amp;title=Epoetin%20Treatment%20of%20Anemia%20Associated%20With%20Cancer%20Therapy%3A%20a%20Systematic%20Review%20and%20Meta-analysis%20of%20Controlled%20Clinical%20Trials+--+Seidenfeld%20et%20al.%2093%20%2816%29%3A%201204+--+&amp;doi=10.1093/jnci/93.16.1204&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/93/16/1204&amp;title=Epoetin%20Treatment%20of%20Anemia%20Associated%20With%20Cancer%20Therapy%3A%20a%20Systematic%20Review%20and%20Meta-analysis%20of%20Controlled%20Clinical%20Trials+--+Seidenfeld%20et%20al.%2093%20%2816%29%3A%201204+--+&amp;doi=10.1093/jnci/93.16.1204&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/short/93/16/1204&amp;title=Epoetin%20Treatment%20of%20Anemia%20Associated%20With%20Cancer%20Therapy%3A%20a%20Systematic%20Review%20and%20Meta-analysis%20of%20Controlled%20Clinical%20Trials+--+Seidenfeld%20et%20al.%2093%20%2816%29%3A%201204+--+&amp;doi=10.1093/jnci/93.16.1204&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/93/16/1204&amp;title=Epoetin%20Treatment%20of%20Anemia%20Associated%20With%20Cancer%20Therapy%3A%20a%20Systematic%20Review%20and%20Meta-analysis%20of%20Controlled%20Clinical%20Trials+--+Seidenfeld%20et%20al.%2093%20%2816%29%3A%201204+--+&amp;doi=10.1093/jnci/93.16.1204&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/93/16/1204&amp;title=Epoetin%20Treatment%20of%20Anemia%20Associated%20With%20Cancer%20Therapy%3A%20a%20Systematic%20Review%20and%20Meta-analysis%20of%20Controlled%20Clinical%20Trials+--+Seidenfeld%20et%20al.%2093%20%2816%29%3A%201204+--+&amp;doi=10.1093/jnci/93.16.1204&amp;link_type=MENDELEY"><img src="/shared/img/common/social-bookmarking/mendeley.gif" alt="Add to Mendeley"
                                            title="Mendeley" /></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/93/16/1204&amp;title=Epoetin%20Treatment%20of%20Anemia%20Associated%20With%20Cancer%20Therapy%3A%20a%20Systematic%20Review%20and%20Meta-analysis%20of%20Controlled%20Clinical%20Trials+--+Seidenfeld%20et%20al.%2093%20%2816%29%3A%201204+--+&amp;doi=10.1093/jnci/93.16.1204&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-1">M<span class="sc">ethods</span></a></li>
                        <li><a href="#sec-8">R<span class="sc">esults</span></a></li>
                        <li><a href="#sec-20">D<span class="sc">iscussion</span></a></li>
                        <li><a href="#fn-group-1">Footnotes</a></li>
                        <li><a href="#ref-list-1">R<span class="sc">eferences</span></a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
         </div>
         <div id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" type="text" name="fulltext" id="header-qs-input" />
                     <input type="hidden" name="submit" value="yes" />
                     
                     <input class="inline_button" type="image" alt="Go" src="/publisher/img/buttons/go.gif" />
                     
                     <div class="adv-search-link"><a href="/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="/content/current"><span>
                                 		  <span class="current-issue-date">
                                    October 2015
                                    </span><span class="toc-citation-volume">
                                    
                                    107
                                    </span><span class="toc-citation-issue">(10)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="/content/current"><img src="/content/107/10.cover.gif" alt="JNCI J Natl Cancer Inst" id="cover" /></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1"
                          src="/resource/htmlfiles/advert.html?p=Right1&amp;u=jnci.oxfordjournals.org/content/93/16/1204.full"
                          width="0"
                          height="0"
                          frameborder="0"
                          scrolling="no"
                          class="resize_ad"></iframe>
                  
               </div>
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/about.html" rel=""
                              title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/contact_us.html" rel=""
                              title="Contact Us">Contact Us</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html"
                              rel=""
                              title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="HTTP://www.oxfordjournals.org/access_purchase/dispatch_dates.html#JNCI.JP"
                              rel=""
                              title="Dispatch date of next issue">Dispatch date of next issue</a>
                           
                        </li>
                        <li>
                           <a href="http://publicationethics.org/" rel=""
                              title="This journal is a member of the Committee on Publication Ethics (COPE)">This journal is a member of the Committee on Publication Ethics (COPE)</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" rel=""
                              title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                        <li>
                           <a href="http://medicine-and-health-careernetwork.oxfordjournals.org/jobseeker/search/results/?t730=&amp;t732=469986&amp;t731=&amp;t733=&amp;t735=&amp;t737=&amp;max=25&amp;site_id=20102"
                              rel=""
                              title="Journals Career Network">Journals Career Network</a>
                           
                        </li>
                     </ul>
                     
                     <p>
                        <a href="http://www.oxfordjournals.org/our_journals/jnci/episodes_2012.html">
                           <img alt="Podcast Logo" style="float:left"
                                src="http://www.oxfordjournals.org/podcasts/podcast_icon_35x35.gif" />JNCI Podcast</a>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Connect with us!</h3>
                     <a href="https://twitter.com/JNCI_Now">
                        <img class="small_margin" alt="Connect with us on Twitter!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/connect_twitter.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     <a href="https://www.facebook.com/thejnci">
                        <img class="small_margin" alt="Connect with us on Facebook!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/facebook.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     
                     <p>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <p>Carmen J. Allegra</p>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/editorial_board.html"
                              rel=""
                              title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor: 12.583</h3>
                     
                     <h3 class="five_year">5-Yr impact factor: 13.584</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>For the Media</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/press_room.html" rel=""
                              title="JNCI PRESS ROOM">JNCI PRESS ROOM</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/for_authors/index.html"
                              rel=""
                              title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html"
                              rel=""
                              title="Self Archiving/Public Access Policy">Self Archiving/Public Access Policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/ ">
                        <img alt="Open access options for authors - visit Oxford Open"
                             src="http://www.oxfordjournals.org/resource/image/promos/oxford_open_small.gif" />
                        </a>
                     <a href="http://www.oxfordjournals.org/oxfordopen/funder_policies/">
                        <img alt="RCUK Wellcome Trust Open Access"
                             src="http://www.oxfordjournals.org/resource/image/wellcome-trust-180x100.jpg" />
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="http://www.oxfordjournals.org/resource/image/pmc-logo.gif" />
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" rel=""
                              title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jnci.oxfordjournals.org/help/citetrack/index.dtl" rel=""
                              title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="/rss" rel="" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" rel=""
                              title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" rel=""
                              title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/classifiedadinprint.html"
                              rel=""
                              title="Classified Advertising">Classified Advertising</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300"];</script>
               </div>
            
            <div class="most-links-box js-marker">
               
               <div class="most-header">
                  
                  <h3>Most</h3>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/6/443?rss=1&amp;ssource=mfr">Breast Density and Cancer Risk: What Is the Relationship?</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/9/713?rss=1&amp;ssource=mfr">The Female Prostate</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/91/14/1194?rss=1&amp;ssource=mfr">Tobacco Smoke Carcinogens and Lung Cancer</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/107/6/djv048?rss=1&amp;ssource=mfr">Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,
                                 Poverty, and State</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/105/23/1799?rss=1&amp;ssource=mfr">Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study</a></li>
                        </ol>
                        	    <a href="http://jnci.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/3/205?rss=1&amp;ssource=mfc">New Guidelines to Evaluate the Response to Treatment in Solid Tumors</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/18/1371?rss=1&amp;ssource=mfc">Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/85/5/365?rss=1&amp;ssource=mfc">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International
                                 Clinical Trials in Oncology</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/13/1107?rss=1&amp;ssource=mfc">New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/1/4?rss=1&amp;ssource=mfc">What Is the Evidence That Tumors Are Angiogenesis Dependent?</a></li>
                        </ol>
                        	  <a href="http://jnci.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom"
                    src="/resource/htmlfiles/advert.html?p=Bottom&amp;u=jnci.oxfordjournals.org/content/93/16/1204.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2105 - Print ISSN 0027-8874</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a> 
               <span>2015</span> Oxford University Press
               
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input type="image" src="/resource/image/buttons/go.gif" alt="Go"
                            class="inline_button" />
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript"
                 src="http://gab.cookie.oup.com/aws-cookie/oup.cookiepolicy.pack.js"
                 defer="defer"></script>
         
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jquery-ui.min.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jcarousellite.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/pf_oiunderbarinit.js"
                 type="text/javascript"></script>
         <script defer="defer" src="/resource/js/underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">
    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <noscript><img src="//ouptag.scholarlyiq.com/ntpagetag.gif?js=0" height="1" width="1"
                 border="0"
                 hspace="0"
                 vspace="0"
                 alt="" /></noscript><script type="text/javascript" src="//ouptag.scholarlyiq.com/ntpagetag.js"></script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   </body>
</html>